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MOLECULAR MECHANISMS OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Apple Long
Anil K. Rustgi
Esophageal squamous cell cancer (ESCC) is the 6th leading cause of cancer related deaths amongst
American men. Although rare, this disease has a high mortality rate with a 5-year survival of 17%.
Incidentally TP53 mutation is the most common genetic alteration in ESCC, along with over expression of
EGFR and CYCLIN D1. We have previously modeled the invasive features of ESCC, through an in vivo-like
3D organotypic culture system, utilizing primary epithelial cells that have been transformed by
overexpression of mutant TP53 and EGFR. From this model, a RNA microarray was performed to
determine critical genes that are upregulated at the front of invasion. WNT10A was found to be over
4-fold upregulated, along with a WNT-signaling gene signature in the invasive cells. We additionally found
that increased WNT10A expression was associated with ESCC, compared to normal esophageal tissue
and that increased WNT10A staining was associated with poor prognosis. Functionally, WNT10A was
determined to induce increased proliferation, migration, invasion and stemness properties in transformed
esophageal cancer cells. In addition to examining the oncogenic properties of WNT10A, we also focused
on generating an in vivo model of mutant TP53 driven ESCC. We utilized a carcinogen, 4-nitroquinoline
1-oxide (4-NQO), as a challenge to induce genetic changes in the background of Tp53 mutation, specific
to the oral squamous, esophagus and forestomach tissues. We found preliminarily that TP53 mutation,
specifically the R172H mutant, can accelerate tumorigenesis as compared to loss of TP53 alone.
Additionally, when RNA-seq was performed on the tumor derived TP53R172H/- and TP53-/- cells, we
found an increase of genes associated with an epithelial to mesenchymal transition (EMT), in the
TP53R172H/- cells. Mesenchymal genes such as Cdh2, Zeb1, Zeb2, Twist, and Snail were increased, while
epithelial genes such as Cdh1, Epcam, and Krt4 were decreased. Altogether, we surmise that the TP53
mutant, R172H, can induce gain-of-function (GOF), oncogenic properties in order to promote
tumorigenesis, potentially by inducing an EMT phenotype.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Cell & Molecular Biology

First Advisor
Anil K. Rustgi

Keywords
Cancer biology, Esophageal Squamous Cell Carcinoma, Mutant p53, Wnt signaling

Subject Categories
Molecular Biology
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/1861

MOLECULAR MECHANISMS OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Apple Long
A DISSERTATION
in
Cell and Molecular Biology
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2015
Supervisor of Dissertation

Anil K. Rustgi, M.D.
T. Grier Miller Professor of Medicine; Chief of Division of Gastroenterology, Perelman
School of Medicine
Graduate Group Chairperson

Daniel S. Kessler, Ph.D.
Associate Professor of Cell and Developmental Biology
Dissertation Committee
Gerd Blobel, Ph.D. Frank E. Weise III Professor of Pediatrics, Perelman School of
Medicine
Makoto Senoo, Ph.D. Assistant Professor of Developmental Biology, University of
Pennsylvania School of Veterinary Medicine
Ellen Puré, Ph.D. Grace Lansing Lambert Professor of Biomedical Science, University of
Pennsylvania School of Veterinary Medicine
Chair: Andy Minn, M.D., Ph. D. Assistant Professor of Radiation Oncology, Perelman
School of Medicine
	
  
	
  

ACKNOWLEDGMENTS
	
  

I would like to thank all of the members of the Rustgi and Nakagawa lab, past and
present for ideas, inspiration, experimental design help, and actual help with experiments
and great advice. I would also like to thank our collaborators, Drs. Andres Klein-Szanto,
Ju-Seog Lee, Shelley Berger, Morgan Sammons, and Jiajun Zhu for their instrumental
help with several of our experiments and experimental design.

	
   ii	
  
	
  

ABSTRACT
	
  
MOLECULAR MECHANISMS OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Apple Long
Anil K. Rustgi
Esophageal squamous cell cancer (ESCC) is the 6th leading cause of cancer
related deaths amongst American men. Although rare, this disease has a high mortality
rate with a 5-year survival of 17%. Incidentally TP53 mutation is the most common
genetic alteration in ESCC, along with over expression of EGFR and CYCLIN D1. We
have previously modeled the invasive features of ESCC, through an in vivo-like 3D
organotypic culture system, utilizing primary epithelial cells that have been transformed
by overexpression of mutant TP53 and EGFR. From this model, a RNA microarray was
performed to determine critical genes that are upregulated at the front of invasion.
WNT10A was found to be over 4-fold upregulated, along with a WNT-signaling gene
signature in the invasive cells. We additionally found that increased WNT10A expression
was associated with ESCC, compared to normal esophageal tissue and that increased
WNT10A staining was associated with poor prognosis. Functionally, WNT10A was
determined to induce increased proliferation, migration, invasion and stemness properties
in transformed esophageal cancer cells. In addition to examining the oncogenic properties
of WNT10A, we also focused on generating an in vivo model of mutant TP53 driven
ESCC. We utilized a carcinogen, 4-nitroquinoline 1-oxide (4-NQO), as a challenge to
induce genetic changes in the background of Tp53 mutation, specific to the oral
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squamous, esophagus and forestomach tissues. We found preliminarily that TP53
mutation, specifically the R172H mutant, can accelerate tumorigenesis as compared to
loss of TP53 alone. Additionally, when RNA-seq was performed on the tumor derived
TP53R172H/- and TP53-/- cells, we found an increase of genes associated with an epithelial
to mesenchymal transition (EMT), in the TP53R172H/- cells. Mesenchymal genes such as
Cdh2, Zeb1, Zeb2, Twist, and Snail were increased, while epithelial genes such as Cdh1,
Epcam, and Krt4 were decreased. Altogether, we surmise that the TP53 mutant, R172H,
can induce gain-of-function (GOF), oncogenic properties in order to promote
tumorigenesis, potentially by inducing an EMT phenotype.
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CHAPTER 1: Introduction

	
  
	
  

1

Esophageal cancer
Esophageal cancer is the sixth leading cause of cancer related deaths worldwide
and the eighth most common cancer type, with an average 5-year survival of
approximately 15-20% (Altekruse SF et al., 2009). Esophageal cancer can be separated
into to two major subtypes, with esophageal squamous cell carcinoma (ESCC) being
more common than esophageal adenocarcinoma (EAC), worldwide. ESCC is most
prevalent amongst the “Asian esophageal cancer belt”, which spans from the Middle East
and across China, suggesting multifactorial components of genetics and environment as
contributors to disease. In the United States, however, EAC is more common and on the
rise, and currently contributes to 80% of all esophageal cancer cases (Taylor et al., 2013;
Mao et al., 2011).
Major risk factors of esophageal cancer include increased age, alcohol use, and
smoking (Mao et al., 2011). Ethanol primarily inhibits DNA methylation and interacts
with retinoid metabolism, in order to induce mutations along the aerodigestive tract (Toh
et al., 2010). Moreover, metabolism of ethanol can lead to further mutagenic properties:
specifically, in certain Asian populations, that may be deficient for expression of
aldehyde dehydrogenase 2 (ALDH2), acetaldehyde build-up may occur, leading to bulky
adduct formation that may escape DNA-repair pathways, and predisposition for ESCC
(Yokoyama et al., 2002). Chemicals in cigarettes that are particularly carcinogenic
include the polycyclic aromatic hydramines and N-nitrosamines (Toh et al., 2010). These
chemicals can induce DNA methylation, bulky DNA-adduct formation along with
genomic instability. Regional risk factors additionally play a strong role in ESCC,
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especially in areas throughout the esophageal cancer belt, where alcohol and tobacco use
is limited. Nitrosamines found in preserved fish and vegetable diets in northeast China
are major contributors of disease (Napier et al., 2014). In northern Iran, frequent drinking
of extremely hot tea has been shown to induce caustic injury and inflammation of the
esophagus, which has been associated with high risk of ESCC (Mao et al., 2011).
The only known precursors of ESCC include esophageal squamous dysplasia
(ESD), with severity of ESD highly associated with ESCC incidence. Primarily, ESD is
characterized by hyperproliferation, nuclear atypia, loss of cellular polarity, and improper
differentiation of the tissue, without invasion into the basement membrane. Dysplasia
grading is stratified into low, middle, and high, depending on the level of infiltration of
the epithelium. When all layers are affected, the pathological grade is considered to be
esophageal intraepithelial neoplasia (EIN). Once the atypical epithelial cells penetrate the
underlying lamina propria, it is considered to be invasive squamous cell carcinoma, with
lymph node dissemination. Once ESCC has occurred, tumors may be of varying
differentiation and rather heterogenous, with features of keratin pearls, cytokeratin
bridges, and desmoplasia within the adventitia; ESCC may also be further stratified based
on differentiation of the tumor, with poorly differentiated tumors correlating with worst
outcome and shorter survival time (Taylor et al., 2013).
Prognosis of esophageal cancer highly correlates with staging at diagnosis.
Commonly, patients present during later stages, when lymphatic and hematogenous
spread has already occurred. Furthermore, since the esophagus wall lacks a serosa,
tumors can expand into adjacent structures in the mediastinum and neck. Staging of
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esophageal cancer is highly dependent on the TNM system. T staging represents the
depth into which the tumor has invaded. T1/T2 tumors, which are usually treated with
surgical resection, indicate tumor invasion into the lamina propria and muscularis,
respectively. T3/T4 tumors require neoadjuvent therapy, of either chemotherapeutics or
radiation, prior to surgical resection, if possible. These later stages usually indicates
invasion into adventitia and adjacent structure. N staging indicates the absence (N0) or
presence (N1) of periesophageal lymph node involvement, which is best assed by
endoscopic ultrasound (EUS). N1 automatically indicates requirement of neoadjuvent
therapy prior to surgical resection. M staging indicates the level of metastatic spread. M0
indicates no tumor spread, as determined by computer tomography (CT) at the most
common sites of metastasis: lung, liver and bone. Metastatic spread is stratified further
into M1a versus M1b, with M1a an indicator of improved survival. M1a indicates spread
to the celiac and cervical lymph node, where as M1b, which is present in 15 to 20% of
ESCC diagnosed, indicates distant spread. All together staging is extremely important in
determining therapeutics and must be assessed appropriately with a variety of modalities,
such as CT, EUS, and

18

F-fluordeoxyglucos positron emission tomography (FDG-PET)

(Rice et al., 2010; Napier et al., 2014).
A vast majority of genes and dysregulated proteins have been associated with
ESCC occurrence and prognosis. The most common genetic alterations of ESCC include
overexpression of Epidermal Growth Factor Receptor (EGFR), CYCLIND1, mutation in
TP53, and inactivation of p15INK4B/p16INK4A, and loss or mislocalization of p120
CATENIN and CADHERIN-1 (E-CADHERIN) (Mandard et al., 2000; Stairs et al.,
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2011; Lin et al., 2009).

Recent sequencing efforts have additionally shown that

NOTCH1, NOTCH3, and FBXW7 were quite frequently mutated in ESCC, along with
members of the WNT/B-Catenin signaling pathway (Song et al., 2014). Our lab has
additionally previously shown the importance of PERIOSTIN in mediating migration,
invasion, and as a diagnostic marker of ESCC (Michaylira et al., 2010; Wong et al.,
2013b; a). One of the most drastic genetic alterations in ESCC is associated with TP53
loss or mutation. Overall, TP53 is estimated to be mutated in 40-50% of all cases of
ESCC. Yet, recent sequencing efforts of ESCC in the Chinese population report
exceedingly high rates of TP53 mutation, from 83 to 93%, with a predominance of
missense mutations (Song et al., 2014; Gao et al., 2014). Most common missense
mutations within TP53 include R175H and R248H, which account for 10% of all TP53
alterations, combined (Petitjean et al., 2007). As TP53 mutation is the most often mutated
gene in ESCC, it is not surprising that it is suspected to be an early event during
pathogenesis. Based on immunohistochemistry (IHC) staining along with sequencing of
microdissected tissue, TP53 mutations are seen even during early dysplasia, suggesting
TP53 mutation may be an initial driver of ESCC progression (Wang et al., 1993).
Embryogenesis of the esophagus
	
  

The esophagus originates as a joint structure with the trachea in a developmental
intermediate known as the anterior foregut. This foregut is derived by ventral folding of
the endodermal epithelial sheet during gastrulation (Wells and Melton, 1999). The
separation

of

these

two

structures
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requires

well-coordinated

cues

from

epithelial/mesenchymal interactions as well as specific cell intrinsic cues to proliferate
and differentiate. Failure of these processes can lead to malformation and birth defects
such as esophageal atresia and tracheoesophageal fistula.
The anterior foregut separates in a ventral/dorsal manner, giving rise to the
trachea and esophagus, respectively. Specific transcription factor expression cues the
distinction between these two tissues; SOX-2 is expressed in the epithelial cells of the
dorsal region, whereas NKX2.1 marks the ventral epithelium (Que et al., 2007; HarrisJohnson et al., 2009). These transcription factors are critical for these cell fate decisions,
as hypomorph mutations in SOX-2 and deletion of NKX2.1 can lead to esophageal
atresia and fistulation (Que et al., 2007; Minoo et al., 1999). Extrinsic signaling factors,
such as WNT signaling (which will be covered more in depth in a later chapter) and bone
morphogenic protein (BMP) signaling have also shown to play a role in this process, as
defects in their signaling also produce esophageal atresia phenotypes in mice (Rodriguez
et al., 2010).
Following separation of the dorsal foregut, a ciliated simple columnar lumen is
formed as a precursor to the esophageal stratified epithelium (Yu et al., 2005). SOX-2
here plays a critical role in inducing the proliferation and stratification of the epithelial
cells, as SOX-2 hypomorph mutant mice maintain columnar structure and develop
goblet-like mucin producing cells (Que et al., 2007). Similarly, TP63 null mice also
exhibit a similar phenotype in the proximal forestomach, which recapitulates the distal
gastroesophageal junction in humans (Daniely et al., 2004; Wang et al., 2011). TP63 is
another critical factor in the induction of stratification of epithelium in both skin and
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esophagus, through its role in maintaining the self-renewal capacity of stratified
epithelial. TP63 null mice notably are born with little or eroded epithelium (Parsa et al.,
1999; Yang et al., 1999). Interestingly, BMP signaling is silenced during the stratification
of the esophageal epithelium, as it may negatively regulate SOX-2 expression, but it is reexpressed shortly after stratification in the suprabasal layers of the esophagus in order to
allow for proper differentiation of the tissue (Domyan et al., 2011; Rodriguez et al.,
2010).
TP53: A potent tumor suppressor
	
  

TP53 was first described as a protein associated with the simian virus 40 large T
antigen in virally transformed cells (Lane and Crawford, 1980; Linzer and Levine, 1979).
Initial descriptions of TP53 suggested that it was acting as an oncogene, as it became
upregulated when cell lines were transformed by viruses, irradiation or chemical
carcinogens. Furthermore, its overexpression was able to immortalize primary cells and
transform them in cooperation with the expression of Ras (Eliyahu et al., 1984). In
actuality, the original clone of TP53 studied was actually a mutant version (DeLeo et al.,
1979; Rotter, 1983). Thus, the wildtype version of the protein was indeed a tumor
suppressor that would become upregulated in response to cellular insults.
TP53 encodes a tetrameric multidomain protein that is important in responding to
a variety of stress signals, such as genotoxic damage, oncogene activation, and loss of
normal cell contact, amongst others (Lane, 1992; Vousden and Prives, 2009). While
primarily a nuclear transcription factor, capable of activating and repressing downstream
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target genes, TP53 has additionally been described to have non-transcriptional functions.
TP53 is composed of three domains: an N-terminal trans-activating (TA) domain, a
central DNA-binding domain (DBD) and a C-terminal oligomerization domain (OD)
(Bullock and Fersht, 2001). Almost every amino acid of TP53 can be modified by
posttranslational modifications, such as phosphorylation, acetylation, ubiquitination,
amongst others, in order to initiate downstream tumor suppressing functions (Meek and
Anderson, 2009). TP53 has been shown to participate in a myriad of functions, including
induction of apoptosis, senescence, cell cycle arrest, DNA damage response, autophagy,
metabolism, miRNA transcription, and inhibition of embryonic cell reprogramming, thus
making TP53 such a potent tumor suppressor (Vousden and Prives, 2009).
Not unexpectedly, TP53 is the most mutated gene in cancer, and is estimated to be
mutated in over 50% of all cancers. Additionally, individuals with germ line mutations in
TP53 have a cancer predisposition syndrome, known as Li-Fraumeni syndrome. Over
70% of TP53 mutations in cancers are missense mutations and 30% of them fall within
one of six hotspot codons in the DBD (Petitjean et al., 2007). The mutations of TP53
generally fall into three categories. (1) Nonsense mutations, which account for the
minority of mutations in esophageal cancer, induce loss of production of full-length
protein. These mutations, when homozygote, lead to TP53 null cells, which do not have
the ability to induce a TP53 tumor-suppression response. (2) Single amino acid
alterations that lead to missense mutations can also cause loss of wildtype TP53
functions. Additionally though, they can also act in a dominant negative fashion if there
is maintenance of the second wildtype allele. Since TP53 binds to DNA in a tetrameric
	
   8	
  
	
  

fashion, one mutated allele can induce hetero-oligermerization to inhibit proper DNA
binding. Of note, mutations in TP53 confer increased stability compared to their wildtype
counterparts due to a combination of mechanisms, which are not completely understood.
Nevertheless, stabilization of the mutant copy over the wildtype protein of TP53 induces
a majority of defunct tetramers. Lastly, a newly accepted notion of mutant TP53 is its (3)
gain-of-function (GOF) oncogenic properties. Given the high propensity of TP53
missense mutations across many cancers, it has been suggested that certain mutations,
specifically at the hotspot codons, can provide greater survival advantage, through GOF
oncogenic properties. GOF is especially apparent when there is loss of heterozygosity of
the second TP53 allele, in order to ensure that no dominant negative effects can occur.
Therefore, in order to most rigorously study GOF properties of mutant TP53,
investigators must perform all studies under TP53 null conditions (Brosh and Rotter,
2009; Oren and Rotter, 2010; Freed-Pastor and Prives, 2012; Oren and Rotter, 2015).
Gain of function roles of mutant TP53
	
  

GOF mutations in the DBD region of TP53 are most common, as they cause TP53
to lose its specificity to DNA sequences, while maintaining transactivation functions
(Petitjean et al., 2007). These mutations can either cause global conformation changes or
interfere with promoter-specific contact. The R175H mutation, a hotspot mutation, for
instance, causes destabilization at a zinc-binding site, which structurally distorts the
conformation of TP53 (Olivier et al., 2010). This mutant may even expose hydrophobic
epitopes that can aggregate into large Β-sheaths that may act as a sponge for other
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proteins. R273H, on the other hand is a contact defective mutant, which cannot bind the
canonic TP53 DNA-binding sites in a sequence specific fashion (Xu et al., 2011). Other
hotspot mutations include G245S, R248W, R249S and R282S (Petitjean et al., 2007).
The prevalence of hotspot mutation sites suggests a specific survival advantage for these
mutations, and thus potentially oncogenic potential of these specific mutants.
Additionally, in esophageal cancer, up to 75% of all tumors with TP53 mutation have
coinciding additional alterations of the second allele (either mutated or promoter
methylated), suggesting that GOF properties may be highly prevalent (Hu et al., 2001).
Some of the first studies to implicate GOF roles of mutant TP53 occurred over 20
years ago. When TP53 null fibroblasts were transfected with mutant TP53, it was shown
that mutant TP53 overexpressing cells had a greater propensity for forming tumors in null
mice, compared to the TP53 null fibroblasts. Transfection of mutant TP53 in a null
human osteosarcoma line also induce greater soft agar plating efficiency, as compared to
the control (Dittmer et al., 1993). This seminal study implicated the potential for
additional oncogenic functions of mutant TP53 and led to decades more of continuing
researching into the mutant TP53 GOF field. In 2004, two groups showed through
independent mouse models the in vivo GOF effects of mutant TP53.

Each group

expressed a knock-in mutation of TP53 at the endogenous promoter, which can be
induced by a tissue specific Cre-Lox system. In a 129S4/SVJae background, mice, with
Protamine-Cre induced knock-in mutations of R172H and R270H of TP53 (equivalent to
R175H and R273H respectively in the human), mice developed carcinomas at higher
frequencies, when compared to TP53 null mice, although lifespan of mice were
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equivalent. While most TP53 null mice succumbed to hematological illness, almost none
developed carcinomas, suggesting the necessity of mutations in TP53 in order to induce
transformation in epithelial cells (Olive et al., 2004). In the C57BL/6 background of
knock-in p53R172H mice, there were no differences in tumor site spectra between mutant
TP53 mice and TP53 null mice. Instead, there was a greater predilection for the mutant
TP53 knock-in mice to develop metastases, as compared to the null controls (Lang et al.,
2004). This phenomenon is reinforced in recent metastasis models utilizing cells derived
from murine pancreatic cancer driven by KRASG12D and TP53R172H mutations. When
these cells were deprived of mutant TP53, there was a decreased propensity of these cells
to colonize into the lungs and liver when injected orthotopically into pancreata. The
mechanism by which mutant TP53 induced increased metastases was shown to be
through repression of TP73/NF-Y complex leading to induction of PDGFΒ
(Weissmueller et al., 2014).
Studies on GOF mutant TP53 indicate that the oncogenic properties of mutant
TP53 can arise from a variety of mechanisms. Specifically, mutant TP53 has been shown
to participate in novel protein-protein interactions, trans-activate novel gene targets, or a
combination of the two. Additionally, since mutant TP53 is normally expressed at rather
high protein concentrations due to its inability to be properly degraded, normally weak
protein-protein interactions can be exacerbated. When mutant TP53 participates in novel
protein-protein interactions, it can either inhibit or potentiate the functions of the binding
partner. Proteins that mutant TP53 have been shown to inhibit include MRE11 and the
TP53 family members, TP63 and TP73 (Freed-Pastor and Prives, 2012). Inhibition of
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MRE11, for instance inhibits its proper binding to the MRE11-NBS-RAD50 complex,
which is required for proper ATM-mediated DNA-repair. Thus mutant TP53 can
potentiate genomic instability in its GOF role (Song et al., 2007). TP53 interaction with
various isoforms of TP63, via the DNA-binding domain can initiate a pro-invasive
phenotype, either through activation of downstream TP63 targets or through induction of
an integrin recycling pathway (Adorno et al., 2009; Muller et al., 2009). Additionally,
mutant TP53 can interact with a variety of transcription factors in order to be recruited to
their discrete binding sites. In turn, mutant TP53 can either trans-activate or repress these
downstream gene targets as its trans-activation domain is not commonly mutated (FreedPastor and Prives, 2012; Muller and Vousden, 2013). These trans-activation domains are
capable of recruiting transcriptional activators such as p300 and TATA binding protein,
in order to induce transcription of novel targets (Di Agostino et al., 2006; Liu et al., 2011;
Dell’Orso et al., 2011). Transcription factors that have been shown to co-opt mutant
TP53’s transactivation functions include NF-Y, SP1, ETS-2, VDR, and SREBP2 (Liu et
al., 2011; Chicas et al., 2000; Do et al., 2012; Stambolsky et al., 2010; Freed-Pastor et al.,
2012) . Downstream functions of mutant TP53 can lead to a variety of transforming roles
including: migration, invasion, proliferation, drug resistance, and induction of genomic
instability (Freed-Pastor and Prives, 2012).
Role of mutant TP53 in 3D organotypic culture of transformed esophageal cells
	
  

Considering the high prevalence of mutations in TP53 in ESCC, our lab generated
cells lines that overexpressed the different TP53 mutations in a transformed setting.
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Primary normal epithelial esophageal cells (EPC2) were obtained from a human biopsy,
and were immortalized by the overexpression of hTERT (Harada et al., 2003). These
immortalized, EPC2-hTERT cells could be further transformed by the expression of a
combination of oncogenes, such as overexpression of EGFR and mutations in TP53
(Okawa et al., 2007). Of note, the wildtype allele of TP53 was maintained in these cells,
while the mutant allele was transgenically overexpressed. These cells were shown to be
transformed by a variety of mechanisms such as through migration, invasion, colony
formation, soft agar growth, and xenograft implant assays (Okawa et al., 2007).
Furthermore, these cells were grown in an in vivo-like 3D organotypic culture
system (OTC), which recapitulated the microenvironment of epithelial cells of the
esophagus (Michaylira et al., 2010). This 3D OTC system consists of a bottom
matrigel/collagen acellular layer, which is overlaid with low passage fetal esophageal
fibroblasts in the middle layer. After seven days, these layers contract into a feeder
matrix, and epithelial cells can be grown on top. These cells can divide in an
asymmetrical fashion in order to induce the stratified layer of the esophageal epithelium.
Furthermore, upon introducing an air-liquid interface, the stratified epithelium can induce
keratinization, which is seen in human skin and mouse esophagus. These 3D culture
systems can be harvested and embedded into paraffin blocks in order to allow for
Hematoxylin and Eosin (H&E) and/or immunohistochemistry (IHC) staining (Kalabis et
al., 2012).
Although the transformed EPC2-hTERT derivatives that have overexpression of
mutant TP53 can induce stratification in this 3D OTC system, they additionally show
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features of invasive downward growth into the fibroblast-enriched matrix. Primarily these
invasive regions are not differentiated and maintain basal cell features, such as strong
TP63 staining, a marker of the undifferentiated epithelial cell (Okawa et al., 2007).
Interestingly, there are different degrees of invasion, with the R175H mutation being the
most invasive. This process was further explored, in order to better understand some of
the mechanisms of mutant TP53-mediated invasion, as a potential GOF property. In order
to do so, our lab utilized laser-capture microdisecction of the invasive and non-invasive
regions of the 3D OTC samples that grew different TP53 mutations (R175H, R248W,
R273H and V143A). We proceeded to harvest RNA from each these sections in order to
perform comparative microarray analysis on the invasive and non-invasive region. One of
the top genes that was upregulated in each microarray set was PERIOSTIN, a
matricellular protein that not only was induced by mutant TP53, but also worked in
concert with mutant TP53 in order to induce a permissive microenvironment to induce
invasion (Ohashi et al., 2010a; Michaylira et al., 2010; Wong et al., 2013b).
Additional pathway analysis was performed on the invasive gene signature, and
from the combination of all the mutants, it was shown that there was a significant
enrichment of the WNT signaling gene signature. Specifically, genes such as WNT10A
and WNT5B were upregulated, while the WNT signaling negative regulator DKK1 was
downregulated across multiple mutants (Long et al., 2015). As the WNT signaling
pathway is frequently dysregulated in over 40% of all ESCC (Song et al., 2014), we
decided to investigate this pathway further, specifically via WNT10A. WNT10A
upreguulation was not only associated in the WNT signaling pathway, but also
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contributed to other significantly enriched pathways, associated with the invasive gene
signature, such as regulation of the epithelial to mesenchymal transition pathway and
induction of human embryonic stem cell pluripotency.
WNTs and the canonical WNT pathway
The WNT family of ligands is critical in both development and disease across all
metazoan species, with conservation from the Hydra vulgaris to the higher vertebrates
(Kusserow et al., 2005). Wnt1 was first cloned in 1982, under the name int1. Notably,
int1 was a common insertion site for the retrovirus, Mouse Mammary Tumor Virus; this
specific insertion could induce the upregulation of the proto-oncogene Wnt1, in order to
induce transformation of mouse mammary tissue (Nusse and Varmus, 1982).
Concurrently, developmental biologists, studying Drosophila melanogaster, were able to
generate mutants that disrupted segment polarity in embryonic development. Wingless
was (Wg), was one of the genes discovered in this mutant screen, along with Armadillo,
Dishevelled, Porcupine, and Arrow (Sharma and Chopra, 1976; Nüsslein-Volhard and
Wieschaus, 1980). Indeed, the Drosophila homologue of int1 mapped closely to
Wingless, with a similar localization pattern of a striped larvae . By the 1990s, the naming
of the gene combined, to form ‘WNT’ (Wingless-related integration site), with Wnt1
(int1) becoming the first member of a family of related genes (Nusse et al., 1991).
Mice and humans have over 19 members in the WNT family, which fall into
twelve subgroups. Between mouse and human, WNTs are conserved 99% at the amino
acid level. While at least eleven WNTs existed in the last common ancestor between
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deuterstomes and arthopods, duplication events occurred over the last 500 million years,
in order to generate many of the paralogs of WNT 3, 5, 7 and 10 (Sidow, 1992).
Interestingly, Drosophila and Caenorhabditis lost some of their WNT homologs, and
only have seven and five WNTs, respectively. WNT10 was duplicated along with the
WNT1-WNT6-WNT10 cluster. Over time, WNT6 was lost from the WNT1-WNT10B
cluster, where as WNT1 was lost from in the WNT6-WNT10A cluster (Nusse, 2001).
Maintenance of two different WNT10 genes may suggest diverse and specific functions of
these two genes in higher organisms, although redundant roles may still exist.
Additionally, this unique grouping of WNT genes suggests coordinated regulation of
each cluster, similar to another developmental grouping, the Hox cluster.
Members of the WNT family are small, secreted proteins, which are cysteine-rich.
Many of these cysteine sites are predicted to form disulfide bonds in order to maintain the
globular structure of WNT. In addition, WNTs are also highly post-translationally
modified with various glycosylation and acylation sites; these modifications contribute to
multiple band formation of overexpressed WNTs, when they are run on an immunoblot.
Glycosylation events are primarily at asparagine residues, and are suggested to preceded
palmitoylation events (Komekado et al., 2007). Perhaps the best-described modification
of WNTs is the palmitoylation of various cysteine and serine residue by the ER protein
PORCUPINE (PORCN) (Willert et al., 2003; Takada et al., 2006). These modifications
are crucial for the recognition of WNTs by WNTLESS (WLS), a sorting receptor that sits
at the golgi membrane and transports WNTs to the plasma membrane (Bänziger et al.,
2006). Mutations in Porcupine in mice lead to embryonic lethality (Barrott et al., 2011;
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Biechele et al., 2011), whereas mutations in human PORCN (an X-linked gene), can lead
to lethality in males and focal dermal hypoplasia in females (Grzeschik et al., 2007;
Wang et al., 2007). These findings suggest the necessity of palmitoylation of WNTs, in
order for proper secretion and signaling functions.
Considering the high levels of lipidation amongst WNTs, it was proposed that
these proteins were highly hydrophobic. Indeed the hydrophobic nature of WNTs eluded
researchers in the ability to purify the protein, for over 30 years. The first purification
was of the murine WNT3A in 2003 (Willert et al., 2003), while the first structure of
WNT

(Wnt8 in Xenopus) was not solved until 2012 (Janda et al., 2012). The

hydrophobic nature of WNTs would suggest its poor ability to diffuse across long
distances extraceullarly. Primarily, WNTs act as morphogens that generate a gradient,
and act as paracrine cellular signals in a concentration dependent manner. Often times,
WNTs act across very short distances, such as across the neuromuscular junction or
within a given stem cell niche (Korkut et al., 2009; Sato et al., 2004). Long-range
functions of WNTs have recently been proposed to involve either binding with other
interacting proteins or through transport via exosomes (Mulligan et al., 2011; Gross et al.,
2012).
Classically, WNT signaling is separated into a canonical and non-canonical
pathway. Canonical WNTs usually include WNT1, WNT3A, and WNT8, and the classic
non-canonical WNT is WNT5A. Yet, depending on cellular context and available
receptors, many WNTs can feed into either pathway (Grumolato et al., 2010). Canonical
WNT signaling is best described by its ability to induce nuclear localization of B	
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CATENIN and activation of its downstream target genes. Non-canonical WNT signaling,
on the other hand, is more diverse and can act antagonistically to canonical WNT
signaling. It is divided primarily into three categories: the planar cell polarity (PCP),
WNT/Ca2+ and JNK pathways (Gómez-Orte et al., 2013). The PCP pathway regulates
cellular polarity during morphogenesis, and is involved in such processes as gastrulation
and neural tube closure. It utilizes mainly the FRIZZLED (FZ) receptors in order to
activate downstream RHOA and JNK effectors (Schambony and Wedlich, 2007; Minami
et al., 2010). In addition to developmental roles, the WNT/Ca2+ pathway can also play a
role in cancer, inflammation, and neurodegeneration (De, 2011). Its main effector is the
activation of phospholipase C, which triggers intracellular calcium release, in order to
activate downstream kinases and phosphatases ultimately toward an N-FAT driven
transcriptional response (Gómez-Orte et al., 2013). The JNK pathway can utilizes ROR2
receptors to induce JUN and ATF2 target genes (Schambony and Wedlich, 2007).
Depending on the WNT, the cell type, and/or the receptor complement, different WNT
signaling pathways can be elicited, suggesting high diversity and specificity of each
context.
The canonical WNT pathway is perhaps the better studied of the two pathways.
Many of the proteins were elucidated through genetic screens and epistasis experiments
in Drosophila, in order to determine the order of the pathway components (Sharma and
Chopra, 1976; Nüsslein-Volhard and Wieschaus, 1980). Canonical WNT signaling is
initiated with the binding of WNT to the FZ family of receptors and the homologue of
Drosophila Arrow, low-density lipoprotein (LDL) receptor-related protein (LRP). In
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addition to WNTs, the FZ/LRP5/6 receptors can also bind to WNT antagonists, such as
DICKKOPF (DKK), in order to disrupt WNT binding (Semënov et al., 2008). Other
inhibitors of WNTs include the secreted Frizzled-related proteins (sFRPs) and WNT
inhibitory protein (WIF), which can sequester away functional WNTs (Bovolenta et al.,
2008). Nevertheless, binding of WNT to its heteromeric receptor complex leads to the
recruitment of DISHEVELED (DVL) to the FZ receptor, and phosphorylation of the LRP
tail by CK1α and GSK3 (Tamai et al., 2004). These coordinated events lead to the
binding of AXIN to the cytoplasmic tail of LRP5/6 (Mao et al., 2001). AXIN is large
scaffolding complex that houses the destruction complex of B-CATENIN, which include
adenomatous polyposis coli (APC) and the kinases CK1α and GSK3. Relocalization of
AXIN to the LRP tail leads to the inhibition of B-CATENIN phosphorylation by
CK1alpha and GSK3, preventing its degradation (Kishida et al., 1998). The build-up of
B-CATENIN induces its nuclear translocation, where it can act with Lymphoid
Enhancer-Binding Factor 1/T cell-specific Transcription Factor (TCF/LEF) binding
partners to induce transcription of target genes (Aberle et al., 1997).
WNTs in development
	
  

The diversity in number of WNTs and their high conservation suggest their
criticalness in multicellular organisms, especially in embryogenesis. One of the first
studies to demonstrate the importance of WNTs in development utilized ectopic
overexpression of a murine Wnt1 mRNA in Xenopus laevis blastomeres at the ventral
end, in order to induce a duplicated dorsal axis (Mcmahon and Moon, 1999). This
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experiment demonstrates the role of WNT signaling in development patterning and
additionally highlights the importance of the temporal and spatial restriction of WNTs.
Over the years, WNTs have been described in a variety of processes in development and
homeostasis including: proliferation, cell fate specification and differentiation, cellular
migration, cell adhesion regulation as well as stem cell maintenance, amongst others.
Wingless, the WNT1 orthologue in Drosophila, in addition to mediating proper
segmental patterning in embryonic and larvae stages, is critical for the proliferation of the
wing discs; as its namesake suggests, mutants are wingless (Giraldez and Cohen, 2003).
Additionally, canonical WNT signaling target genes include MYC and CCND1 in colon
cancer cells (He et al., 1998; Shtutman et al., 1999), implicating a role of WNT signaling
in proliferation in specific cellular contexts.
Knockout models in mice validated additional roles of WNTs and their signaling
pathways in embryogenesis. Almost every murine WNT molecule has been knocked out
either alone or as a double knockout with other WNTs. Many of these knockout mice are
embryonic or perinatal lethal due to the developmental defects. Herein, I provide a few
examples to demonstrate the varied tissue types affected by WNTs. WNT1 knockout mice
do not form midbrains and suffer from ataxia when viable, but succumb shortly after
birth (Thomas and Capecchi, 1990; Mcmahon and Bradleyt, 1990). Similarly, the
WNT1/WNT3 compound knockout mice are embryonic lethal by E.18.5 with reduced
numbers of neural crest precursors (Ikeya et al., 1997), suggesting that WNT1 and
WNT3A may have redundant roles in induction of proliferation. WNT2 is expressed
embryonically at the mesenchymal component of the ventral foregut, and when knocked
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out in mice, leads to embryonic lethality due to lung hypoplasia and reduction of NKX2.1
expression (Goss et al., 2009). This phenotype is exacerbated with concomitant knockout
of WNT2B and is also observed in WNT7B null mice (Goss et al., 2009; Shu et al., 2002).
WNT10B knockout mice, interestingly, develop normally, potentially due to
compensation by the expression of WNT7B. With aging, WNT10B null mice do exhibit a
decrease in bone density (Stevens et al., 2010). Additionally, WNT10B null myoblasts
displayed increased capability to form adipocytes, consistent with previous described
work, demonstrating WNT10B’s role in inhibiting adipogenic differentiation (Ross et al.,
2000; Cawthorn et al., 2012) (Ross 2000). WNT10B mutation concurrently has been
shown to be associated with a propensity for obesity in humans (Christodoulides et al.,
2006).
The WNT10A knockout mouse has not been fully described, but functional aspects
of WNT10A in development can be surmised by its mutation in human disease. WNT10A
is one of the primary genes mutated in odontyl-onychol dermal dysplasia (OODD) and
Schopf-Schulz-Passarge syndrome (SSPS), which are both characterized by a variety of
ectodermal dysplasias, affecting the hair, teeth, nail, skin, and tongue (Cluzeau et al.,
2011). Prominent phenotypes of individuals with WNT10A missense and nonsense
mutations include smooth tongues, barrel shaped teeth, and palmar plantar keratoderma
(Tziotzios et al., 2014). These phenotypes suggest a role of WNT10A in proliferation and
differentiation of the ectodermal layer of these tissue types. Localization studies of
Wnt10a expression in the embryonic mouse show that Wnt10a predominates at the
surface ectoderm, and more specifically in epithelial cells of the anterior apical
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ectodermal ridge (AER) (Summerhurst et al., 2008). Wnt10a expression has additionally
been implicated during hair follicle morophogenesis. The proliferation and downward
growth of the hair follicle placode is a well-orchestrated process involving careful
communication between the epithelial and mesenchymal layers. During embryonic day
(E) 14.5 of mouse, Wnt10a is expressed throughout the epidermis of the skin, but during
the start of the hair follicle growth cycle, at E18.5, its expression condenses in the highly
proliferative hair follicle placode. As hair follicle morphogenesis progresses, Wnt10a
expression relocates to the inner root sheath. During adult homeostasis, Wnt10a’s
expression pattern is similar to its embryonic counterpart. Its expression condenses at the
dermal papilla during the start of anagen (growth phase in hair follicle) and then inhabits
the inner root sheet during anagen before it is shut off during telogen (rest phase) (Reddy
et al., 2001). Our own work demonstrates that in addition to ectodermal surfaces of
mouse embryo and the growth stages of adult hair follicles, WNT10A is highly localized
to the E14.5 esophagus, during stratification induction by SOX2 and TP63 activity.
Interestingly, no esophageal phenotypes have been reported in patients with WNT10A
mutation, suggesting potential redundant roles of other WNTs during esophageal
development and homeostasis.
WNT pathway in cancer
	
  

Considering the varied functions of WNTs in development, it is unsurprising that
WNT signaling can also contribute to disease. Many diseases and developmental defects
have been alluded to previously. The primary focus of this next section will be to
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describe the varied roles of WNTs and members of its pathway in cancer. Of note, while
in many cases, upregulation of canonical WNT signaling can lead to increased
proliferation, there are exceptions, in which active WNT signaling may be associated
with improved survival in human cancers (Anastas and Moon, 2013). APC was the first
described member of the WNT pathway to demonstrate an association with human
cancer. Based on its namesake, germline APC mutations were frequently seen in patients
with a hereditary cancer predisposition syndrome, familial adenomatous polyposis (FAP),
which largely affects the large intestines (Kinzler et al., 1991; Nishisho et al., 1991).
These mutations would lead to truncation of APC, and its inability to mediate binding of
the B-CATENIN destruction complex (Groden et al., 1991). APC is also incidentally
mutated in 84% of all sporadic colorectal cancer cases (Ashton-Rickardt et al., 1989).
In addition to APC, many other components of the B-CATENIN destruction
complex are frequently mutated in human cancer. Truncation of AXIN or missense
mutations in the X-chromosome linked Wilms tumor (WTX) gene, both lead to
destabilization of the B-CATENIN destruction complex (Salahshor and Woodgett, 2005;
Major et al., 2007). AXIN mutations are frequently seen in hepatocellular carcinoma,
where as WTX is oftentimes mutated in Wilms tumor, a pediatric kidney cancer (Satoh et
al., 2000; Rivera et al., 2007).

Mutations in CTNNB1 itself, specifically at

phosphorylation sites in the N-terminal, inhibit its ability to be ubiquitinated and
destroyed. Although these mutations occur in only 1% of colorectal cancer cases, they are
more frequently seen in other cancers such as medulloblastoma, hepatocellular
carcinoma, as well as Wilms tumors (Koesters et al., 1999; Polakis, 2007).
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WNT receptors and inhibitors can also be dysregulated in human cancers.
Receptor upregulation can lead to activation of canonical WNT signaling. FZ7 is
frequently upregulated in triple-negative breast cancer; coincidentally in vitro assays
indicate that its knockdown in both triple-negative breast cancer and hepatocellular
cancer cells can lead to reduction of xenograft tumor growth (Yang et al., 2011; Wei et
al., 2011). Truncation mutations in LRP5 are prevalent in parathyroid cancer and
associate with reduced proliferation and increased B-CATENIN activity in xenograft
models and cell culture (Björklund et al., 2007). LRP5 is additionally a candidate gene of
the frequently amplified site 11p13.2 in esophageal cancer (Shi et al., 2014). As
previously mentioned, sFRPs can bind to FZ receptors to block the transmission of WNT
signaling. In cancers such as colorectal, medulloblastoma and pancreatic adenocarcinoma
sFRP1 is hypermethylated, and down-regulated (Suzuki et al., 2004; Vincent et al., 2011;
Kongkham et al., 2010).
Finally, overexpression of WNTs themselves is commonly seen in many human
cancers. Similar to murine mammary tumors, human breast cancer is also associated with
increase expression of WNT1 (Wong et al., 2002). Interestingly, WNT2 was shown to be
highly expressed in esophageal cancer, specifically within the tumor-associated
fibroblasts. Secreted WNT2 was shown to promote proliferation and migratory ability of
the epithelial cells in cell culture (Fu et al., 2011). WNT5A, on the other hand, can play a
more complicated role in cancer. In some cases, WNT5A can act as a tumor suppressor,
and its expression can inhibit proliferation, migration and invasiveness in thyroid tumor
and colorectal cancer cell lines (Kremenevskaja et al., 2005). In gastric cancer though,
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WNT5A was shown to promote cell migration by induction of the focal adhesion kinase
(FAK); its upregulation is additionally associated with poorer prognosis (Kurayoshi et al.,
2006).
The role of WNT10A in cancer has also been briefly touched up in the recent
literature. While it has not be classified as a canonical or non-canonical WNT, based on
homology to WNT10B, which has been confirmed to be a canonical WNT, and based on
its expression pattern in hair follicle morphogenesis, in relation to induction of nuclear BCATENIN, it is highly suggested to act as canonical WNT. The first suggestion of
WNT10A playing a role in cancer, occurred in 2001, when it was published that WNT10A
mRNA expression levels were upregulated in a variety of gastrointestinal cancer cell
lines, including several esophageal cancer cell lines (Kirikoshi et al., 2001a).
Upregulation of WNT10A is also seen in chronic lymphocytic leukemia, as compared to
normal B-cells (Lu et al., 2004). Conflictingly, WNT10A has been shown to be
downregulated in a mesenchymal population of oral squamous cell carcinoma cells, via
DNA hypermethylation at a nearby CpG island (Kurasawa et al., 2012). In these previous
reports, WNT10A has only been shown to be correlative with certain cancer types,
without specificity to mechanism. In renal cell carcinoma, however, WNT10A was
determined to play a definitive role in enhancing proliferation, migration, invasion and
chemoresistance, through its induction of active Β-CATENIN. WNT10A expression is
also associated with poorer survival, especially in concert with high nuclear Β-CATENIN
and CYCLIND1 staining (Hsu, 2012). We will present data demonstrating the
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relationship between WNT10A and ESCC, as well as its functions in tumorigenic
properties (Figure 1).
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Figures and figure legends
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Figure 1

Figure 1. Molecular mechanisms of esophageal cancer. Model demonstrating that
mutant TP53 (R175/2H) can drive tumorigenesis and invasion both in vitro and in vivo.
Through a mutant TP53-driven mouse model of ESCC, we demonstrate that mutant TP53
can promote an epithelial to mesenchymal gene signature. Additionally, in both models,
we demonstrate the upregulation of WNT10A, which can promote proliferation,
migration, invasion and stemness properties in vitro.
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CHAPTER 2: WNT10A promotes an invasive and self-renewing phenotype in
esophageal squamous cell carcinoma
	
  

The data in chapter 2 have been published in Carcinogenesis.
Long A, et al., 2015. Carcinogenesis Apr 23; 36 (5); 598-606
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Abstract
Esophageal cells overexpressing Epidermal Growth Factor Receptor (EGFR) and
TP53 mutation can invade into the extracellular matrix when grown in 3D organotypic
cultures (OTC) and mimic early invasion in esophageal squamous cell carcinoma
(ESCC). We have performed laser capture microdissection with RNA microarray
analysis on the invasive and non-invasive tumor cells of TP53R175H overexpressing OTC
samples to determine candidate genes facilitating tumor invasion. WNT10A was found to
be >4-fold upregulated in the invasive front. Since WNT10A is also prominently
upregulated during placode promotion in hair follicle development, a process that
requires epithelial cells to thicken and elongate, in order to allow downward growth, we
hypothesized that WNT10A may be important in mediating a similar mechanism of
tumor cell invasion in ESCC. We have found that WNT10A expression is significantly
upregulated in human ESCC, when compared with normal adjacent tissue. Furthermore,
high WNT10A expression levels correlate with poor survival. Interestingly, we observe
that WNT10A is expressed early in embryogenesis, but is reduced dramatically
postnatally. We demonstrate that overexpression of WNT10A promotes migration and
invasion, and proliferation of transformed esophageal cells. Lastly, we show
that WNT10A overexpression induces a greater CD44High /CD24Low population, which are
putative markers of cancer stem cells, and increases self-renewal capability. Taken
together, we propose that WNT10A acts as an oncofetal factor that is highly expressed
and may promote proper development of the esophagus. During tumorigenesis, it is
aberrantly overexpressed in order to promote ESCC migration and invasion, and may be
linked to self-renewal of a subset of ESCC cells.
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Introduction
Esophageal squamous cell carcinoma (ESCC) is the sixth leading cause of cancerrelated death amongst American men, and sixth overall cause worldwide (Altekruse SF,
et al., 2009). Common genetic alterations of ESCC include overexpression of Epidermal
Growth Factor Receptor (EGFR) and CYCLIND1, as well as mutation in TP53 and either
loss or mislocalization of p120 CATENIN (Enzinger and Mayer, 2003; Lu et al., 2003;
Song et al., 2014; Stairs et al., 2011). A recent genome sequencing effort from a cohort of
158 Chinese ESCC samples revealed that WNT and NOTCH signaling pathways are also
highly deregulated (Song et al., 2014).
We have shown previously that overexpression of mutant TP53 (R175H) along
with EGFR in primary immortalized esophageal epithelial cells induces transformation
(Okawa et al., 2007). Furthermore, when these engineered cells were grown in 3D
organotypic culture (OTC), which mimics the stratified epithelium and its crosstalk with
the underlying stroma, they invade into surrounding stroma, similar to early invasion
observed in ESCC (Okawa et al., 2007).To understand what molecular mechanisms may
be responsible for invasion, we dissected out the invasive and non-invasive regions from
these 3D cultures and performed comparative microarray analysis (Michaylira et al.,
2010). PERIOSTIN, was found to be the highest upregulated gene, and has been
described previously as a potential biomarker for ESCC (Wong et al., 2013b; a).
Strikingly, we observed additional dysregulation of a variety of Wnt pathway genes, such
as upregulation of WNT ligands, WNT10A, WNT5B, and downregulation of the WNT
pathway inhibitor DKK1 (Michaylira et al., 2010). WNT signaling is critical in the
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embryonic development of different invertebrate and vertebrate organisms. In particular,
WNT signaling is critical in the regulation of axis patterning, cell fate specification, cell
proliferation and cell migration during development (Clevers, 2006; Macdonald et al.,
2009). WNT ligands are secreted glycoproteins that are cysteine-rich and comprise a
short N-terminal signal sequence with a mature segment that has variable length (Willert
and Nusse, 2012). There are nearly 20 different WNT proteins, the expression of which is
spatially and temporally regulated during development, and maintain homeostasis and
drive cancers in a context dependent manner (Polakis, 2000; Staal et al., 2008). Mouse
WNT10A is synthesized as a 417 amino acid precursor that contains a 382 amino acid
mature region, the latter of which contains two potential glycosylation sites. Mouse, rat
and human WNT10A are highly conserved and WNT10A’s amino acid sequence is 64%
identical to WNT10B (Wang and Shackleford, 1996; Kirikoshi et al., 2001b).
Developmentally, WNT10A is best studied in the context of ectodermal lineages. It is
studied primarily in the deregulation of ectodermal tissues resulting in a variety of
disorders classified as: odonto-onychal dermal dysplasia (Adaimy et al., 2007; Bohring et
al., 2009). Manifestation of WNT10A mutations in humans can result in defects in
dentinogenesis,

tooth

morphogenesis,

odontoblast

differentiation,

hair

follicle

development, nail formation, papillae of the tongue and sweat gland, and regeneration of
the epidermis (Bohring et al., 2009; Nawaz et al., 2009; Cluzeau et al., 2011).
Contributing to this developmental phenotype, WNT10A messenger RNA has been
shown to strongly localize to the dermal condensates during the earliest stages of
embryonic hair follicle formation and postnatal anagen (Reddy et al., 2001). This process
requires coordinated cross-talk between epithelial cells and underlying dermal cells in
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order to facilitate elongated epithelial cell down growths (Reddy et al., 2001; Itin, 2014).
Moreover, publically available in situ hybridization data indicates that in addition to
localization in ectodermal tissues, WNT10A messenger RNA also strongly localizes to the
embryonic esophagus at embryonic day 14.5, suggesting a role in esophageal
development (Visel et al., 2004). WNT10A has been previously implicated in a variety of
cancers and has been shown to promote proliferation, migration and chemoresistance in
renal cell carcinoma cell lines by regulation of Β-CATENIN (Hsu et al., 2012; Li et al.,
2001; Kirikoshi et al., 2001a; c). Other reports suggest that WNT10A is also upregulated
in esophageal cancer, gastric and colon cancer cells and tumors (Kirikoshi et al., 2001a).
By contrast, the WNT10A promoter has been suggested to be hypermethylated in
head/neck squamous cell carcinoma and oligodendroglioma cell lines (Kurasawa et al.,
2012; Ordway et al., 2006). Herein, we show that WNT10A is upregulated both in early
development, as well as in early and late stages of ESCC, due its ability to promote
proliferation, migration, invasion and self-renewal. Taken together, we suggest that
WNT10A may act as an oncofetal factor in the context of both esophageal development
and tumorigenesis.
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Results
WNT10A is preferentially expressed in the invasive compartment of transformed
epithelial cells in 3D OTC
We have identified WNT10A as a prominent upregulated gene in invasive versus
non-invasive EPC2-hTERT-EGFR-TP53R175H cells grown in 3D OTC, an in vivo like
model of ESCC (Michaylira et al., 2010). WNT10A was a strong candidate for further
study, as it was upregulated significantly in the invasive region of another TP53 mutant
(R248W) (unpublished data). Furthermore, based on pathway analysis of all TP53
mutants analyzed (R175H, V143A, R248W and R273H), there was a significant
enrichment for WNT/Β-catenin signaling genes (Figure 1). Interestingly, WNT10A was
included in other significantly upregulated pathways, such as regulation of epithelial to
mesenchymal transition and human embryonic stem cell pluoripotency (Supplementary
Table 1).
We sought to confirm this expression of WNT10A through immunofluorescent
staining of 3D OTCs. WNT10A stained predominately in the cytoplasm of epithelial
cells. Strikingly, we saw stronger staining within the invasive regions (I), as compared
with the basal non-invasive (NI) regions (Figure 2A). We quantified the mean intensity of
the staining, and saw that invasive regions had an ~4-fold increase in fluorescent level as
compared with the basal layer (Figure 2B). We next confirmed that WNT10A expression
was increased through quantitative PCR. Using a non-invasive cell line, EPC2-hTERTEGFR-empty vector cells, we confirmed that the more invasive EPC2-hTERT-EGFRTP53R175H cells expressed significantly higher levels of WNT10A messenger RNA
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(Figure 2C). These results were replicated with several primer sets for WNT10A as
compared with GAPDH and HPRT (data not shown).
WNT10A overexpression promotes migration and invasion in transformed
esophageal keratinocytes
Since WNT10A was upregulated in the invasive front of transformed esophageal
cells grown in 3D OTC, we next wanted to determine the role of WNT10A in mediating
migration and invasion. To test this hypothesis, we first generated EPC2- hTERT-EGFRR175H cells that either overexpressed WNT10A or an empty vector control (herein
known as WNT10A and empty vector, respectively). We confirmed WNT10A expression
by western blot (Figure 3A). Several bands were visualized for WNT10A, indicative of
posttranslational modifications, such as glycosylation and lipidataion, mainly at the 40
and the 50 kD molecular masses (Willert and Nusse, 2012). Interestingly, overexpression
of WNT10A resulted in a slight increase in β-catenin protein (Figure 3A), suggesting
increased stabilization of total β-catenin. WNT10A overexpressing cells exhibited
increased migratory and invasive capability, as compared with empty vector controls in
Boyden chamber assays (Figure 3B and C). WNT10A cells exhibited also a significant
increase in proliferative ability (Figure 3D).
WNT10A promotes a self-renewal phenotype
Based upon our microarray results, WNT10A was suggested to be important in a
category of genes that promote stem cell pluoripotency, along with genes such as WNT5B
and SOX2. We therefore wanted to investigate the role of WNT10A in stemness marker
expression, as well as its ability to promote self-renewal through single sphere assays.
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CD44, a cell surface marker for hyaluronic acid, has been previously implicated as a
putative stem cell marker in ESCC, and has been suggested to be regulated by the
WNT/Β-catenin signaling pathway (Wielenga et al., 1999; Zhao et al., 2011).
Additionally, CD44High and CD24Low expressing cells have also been described to
represent a tumor-initiating population with mesenchymal-like properties (Al-Hajj et al.,
2003; Mani et al., 2008). By fluorescence-activated cell sorting-analysis, WNT10A
overexpressing cells exhibited a marked increase in CD44High and decrease in CD24Low
cells (Figure 4A), resulting in a nearly 2-fold increase in CD44High/ CD24Low cells with
WNT10A overexpression (Figure 4B). We next performed single cell sphere formation
assays in ultra-low attachment plates in the presence of sphere-promoting media.
WNT10A overexpressing and empty vector control cells were plated in a single cell
suspension of 100 cells per well. After 7 days, there was a significant increase in the
average number of spheres formed per well in the WNT10A overexpressing cells as
compared with control cells (Figure 4C), although there was no difference in the size of
the spheres that formed. Together, these data demonstrate that WNT10A increases
migratory and invasive capabilities and promotes a shift toward CD44High cells as well as
self-renewal.
WNT10A expression in esophageal development and ESCC
WNT10A has been implicated previously to be upregulated during early follicle
morphogenesis as well as in a variety of other ectodermal tissue types (Reddy et al.,
2001; Narita et al., 2005). WNT10A is rarely expressed in the normal adult mouse
esophagus. Interestingly though, RNA in situ hybridization data of whole mount embryos
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suggest that in addition to ectodermal lineages, WNT10A is also expressed in the
developing esophagus (Visel et al., 2004). To confirm this finding, we conducted
WNT10A IHC in the esophagus at embryonic days (E) 12.5, 18.5, postnatal day (P) 1 and
adult tissue. We found that WNT10A is expressed as early as E12.5, but exhibits the
strongest staining at E18.5 (Figure 5A). Interestingly, by P1, WNT10A staining is mostly
abrogated, although there may be some residual low levels. In normal adult stages,
WNT10A is expressed minimally. This expression pattern suggests that WNT10A may
play a role in the development of the early mouse esophagus.
In order to examine WNT10A expression in pre-malignant and malignant stages
of ESCC, we utilized a mouse model of ESCC. The 4-NQO is a quinolone derivative that
causes DNA-adduct formation similar to carcinogens in tobacco, leading to oral
squamous and esophageal dysplastic lesions, similar to that of human head neck
squamous cell and esophageal carcinomas (Tang et al., 2004). In mice treated with 4NQO ad libitum in drinking water, we saw increased hyperplastic and dysplastic lesions
in the esophagi, with downward growths into the submucosa, consistent with invasive
cancer, as compared with mice on water (control) (Figure 5B). Interestingly, 4-NQOtreated mice exhibited greater cytoplasmic WNT10A staining in the esophagi, especially
in the invasive regions, as compared with control mice (Figure 5B). We additionally
screened a panel of ESCC cell lines via western blot analysis for expression of WNT10A.
As compared with immortalized primary epithelial cells (EPC2-hTERT), we saw an
increase in WNT10A expression in three out of the eight ESCC cell lines screened
(Figure 5C), namely TE6, TE10 and TE11.
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In order to determine if WNT10A expression could also serve as a biomarker for
ESCC prognosis, we utilized a tumor microarray (TMA) of 92 normal-matched ESCC
tumors and 40 additional tumors, along with 5-year survival data on the patients. IHC
indicated a faint nuclear pattern in samples from normal esophagus samples, while highgrade dysplasia and invasive tumors presented with overall stronger cytoplasmic staining
(Figure 5D). An independent pathologist blinded to patient prognosis status scored the
TMA for cytoplasmic signal (Cy0, Cy1, Cy2 and Cy3). Interestingly, most normal tissues
expressed either very low (Cy1) or no (Cy0) staining, whereas tumor tissues were mostly
scored as Cy2 or Cy3 (Figure 5E). When the tumor samples (n = 132) were stratified for
5-year survival, there was a decrease in median survival time (MST) between the high
expressers (Cy2, Cy3) MST = 17.5 months versus the low expressers (Cy0, Cy1)
MST = 33.5 (Figure 5F). Additionally, there was a significant (P = 0.0322) decrease in
overall survival in the high expressers, based upon the Gehan–Breslow–Wilcoxon test,
and was trending (P = 0.0916), based on Log-rank. Taken together, these findings
suggest that WNT10A is over-expressed in ESCC tumors and cell lines, as well as in
early esophageal development in the mouse, and that it may be an important biomarker
for poor survival in ESCC.
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Discussion
WNTs are critical signaling factors, required for the development of numerous
tissue types, as well as maintenance of homeostasis in regenerative tissues, such as of the
gastrointestinal tract and the skin. Hence, dysregulation of the WNT signaling cascade
leads to a variety of cancers and diseases. Herein, we have demonstrated WNT10A to be
expressed in mouse esophageal development, peaking at embryonic day 18.5 but
diminished substantially postnatally. It is further re-expressed during esophageal
carcinogenesis as observed in both a mouse model of esophageal epithelial dysplasia as
well as in human ESCC. These findings suggest that WNT10A may serve as an oncofetal
factor in the esophagus.
Interestingly, WNT10A embryonic expression has been described in another
context of esophageal development. Notably, FOXA3Cre;Cdx2 conditional knockout
mice, which exhibit esophagealization of the intestine, express increased levels of
WNT10A in both the mutant intestines, as well as the embryonic esophagus, as these
mice are embryonic lethal (Gao et al., 2009). In conjunction with our data, these findings
would lend credence to the premise that differentiation of the esophagus during late
development may involve WNT10A. SOX2 is a critical transcription factor, also highly
expressed in embryonic development of the esophagus. It is vital in the division of the
trachea and the esophagus, in order to promote a single esophageal tube, as well as
fostering the stratified squamous epithelium within the esophagus (Que et al., 2007). In
adult life, SOX2 is limited to the basal compartment of esophageal epithelial cells, where
it promotes proliferation and differentiation (Que et al., 2007). In other squamous
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epithelial types, both SOX2 and WNT10A have been shown to be important in normal
development. Interestingly, Sox2 hypomorphic mice and humans carrying WNT10A
mutation both present with malformation of the fungiform papillae, and ultimately
smooth tongues, as WNT signaling has been shown to drive SOX2 expression (Adaimy
et al., 2007; Okubo et al., 2006). These observations suggest a potential connection
between WNT10A driving SOX2 expression in esophageal development. Indeed, SOX2
is amplified in ESCC (Bass et al., 2009), and it would be interesting to determine to what
extent WNT10A and SOX2 are overexpressed concurrently in ESCC.
Employing a 3D OTC model of ESCC, we found that WNT10A is upregulated in
the invasive front compared with the non-invasive epithelium. We further demonstrate
that overexpression of WNT10A enhances esophageal cells ability to proliferate, migrate
and invade. Loss of function or germline mutation of WNT10A specifically leads to
malformation of ectodermal appendages during development. These developmental
processes require careful communication between epithelial and mesenchymal lineages,
for proper migration of epithelial cells to form placodes and eventually ectodermal tissues
(Itin, 2014). Specifically, during the hair follicle development, and then later in anagen, a
period of growth during the hair follicle cycle, WNT10A is upregulated near the dermal
condensate and later dermal root sheet, and may be required for the downward growth of
the hair follicle (Reddy et al., 2001). Therefore, we propose that WNT10A may be
normally required for epithelial migration and proliferation during development, and that
the oncogenic state is co-opting a developmental process to facilitate carcinogenesis. This
pattern is frequently seen in the context of other oncofetal factors.
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We also observe that WNT10A expression is also increased in an ESCC TMA
when compared with adjacent normal esophagus, and correlates with decreased MST.
Patients with ESCC that express higher WNT10A levels had an overall significant
decrease in 5-year survival time, as well. These data suggest that WNT10A can annotate
the invasive compartment of ESCC and could potentially be used as a biomarker for
poorer prognosis in ESCC. Similarly, WNT10A has been shown to be upregulated in
renal cell carcinoma biopsies and drives proliferation, migration and chemoresistance of
renal carcinoma cell lines (Hsu et al., 2012). Taken together, these data suggest that
WNT10A can act as an oncogene in a variety of tissue types.
We additionally demonstrated that WNT10A could induce stem cell-like
properties by promoting self-renewal. These data are supported by our pathway analysis
of invasive mutant TP53 cells, which suggests that in addition to epithelial to
mesenchymal transition, WNT10A may also play a role in maintaining embryonic stem
cells. Indeed, WNT10A is secreted by mammary stem cells and it may be required for
maintaining this population (Ji et al., 2011). Wnt signaling is also required for the
maintenance of a variety of stem cell niches, such as in intestinal crypts and
hematopoietic systems (Korinek et al., 1998; Reya et al., 2003). Interestingly, we have
demonstrated previously that PERIOSTIN, a type of matricellular protein involved in
remodelling the tumor stroma during tumor cell invasion, is upregulated in ESCC,
mediates ESCC invasion and is critical in tumorigenesis in vivo (Michaylira et al., 2010;
Wong et al., 2013b; a; Wong and Rustgi, 2013). Indeed, metastatic tumor cells induce
stromal PERIOSTIN expression in the secondary target organ (e.g. lung) to initiate
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colonization (Malanchi et al., 2012; Holland et al., 2013). PERIOSTIN is needed for
cancer stem cell maintenance and recruits WNT ligands for increased WNT signaling in
cancer stem cells (Malanchi et al., 2012). Whether PERIOSTIN and WNT10A interact in
this context is an area for future investigation.
Our study is the first report to demonstrate a role for WNT10A in both esophageal
development and in tumorigenesis. Our data suggest that in a TP53 mutant background,
WNT10A mediates tumor cell migration and invasion, while increasing a population of
self-renewing CD44High cells. Interestingly, up to 83% of ESCC cases exhibit mutant in
TP53, while altered genes in the WNT pathway represent almost 85% cases of ESCC
(Song et al., 2014). These mutations may work synergistically to promote more
aggressive and invasive tumors in ESCC.
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Materials and methods
Network analysis
Ingenuity Pathway Analysis was used to identify potential upstream regulators
that control gene expression patterns enriched in invasive TP53 mutant cell lines. The
analysis is based on prior knowledge of expected effects between transcriptional factors
and their target genes stored in the Ingenuity Knowledge Base (Krämer et al., 2014).
Briefly, the analysis examines the known targets of each transcription factor in the
signature and compares their direction of change (expression in invasive relative to the
non-invasive gene signature) to what is expected from the literature. If the direction of
change is consistent with the literature across the majority of targets, then the regulator is
predicted to be active in invasive cells, whereas if the direction of change is mostly
inconsistent (anti-correlated) with the literature, then the regulator is predicted to be
inactive in invasive cells. Regulation z-score was used to estimate the activation state of
the regulators. The overlap P values generated by Fisher’s exact test were used to
estimate the statistical significance of overlap between the dataset genes and the genes
regulated by a regulator.
Cell culture
EPC2-hTERT cells and derivatives, established and extensively characterized by
us, were grown in keratinocyte serum-free media (Invitrogen, Carlsbad, CA),
supplemented with 40 µg/ml of bovine pituitary extract, 1ng/ml epidermal growth factor
and 1% penicillin/streptomycin, as described previously (6,7,32). The TE series human
ESCC cells were a gift from Dr. Nishihira who established the cell lines and were grown
in Dulbecco's modified Eagle's medium supplemented by 10% fetal calf serum (Sigma–
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Aldrich, St. Louis, MO) and 1% penicillin/streptomycin (Invitrogen) as described
previously (Nishihira et al., 1993; Nakagawa et al., 1995). The earliest frozen stocks of
all cell lines have been stored at the Cell Culture Core of the University of Pennsylvania.
We have propagated cells from frozen stocks of the original vials that were authenticated
by short tandem repeat analysis for highly polymorphic microsatellites FES/FPS,
vWA31, D22S417, D10S526 and D5S592 as performed by the Cell Culture Core to
validate the identity of cells by comparing cells at the earliest stocks we have and those
grown >8–12 passages. All cell lines have been tested for mycoplasma contamination on
a regular basis. WNT10A was a gift from Marian Waterman (Addgene plasmid # 35920),
and was subcloned into pBabe-Blast empty vector (Najdi et al., 2012). Retroviral
spinfection was performed as described previously (Michaylira et al., 2010). 3D OTCs
Epithelial cells were grown as described (Kalabis et al., 2012), in order to recreate the
microenvironement of ESCC, by supplying extracellular membrane components,
including collagen and fetal esophageal fibroblasts.
Mouse treatments
4-nitroquinoline 1-oxide (4-NQO) experiments were performed as described
previously and under Institutional Animal Care and Use Committee (IACUC) approval
(Tang et al., 2004). In brief, 6-week-old C57Bl/6 and mixed background mice were given
10mg/ml of 4-NQO diluted in 10% propylene glycol in their drinking water ad libitum.
Mice were randomized amongst littermates into control versus treatment groups. Mice
were euthanized either directly after treatment or after a 12-week wash out period. Three
to five mice, per condition, were euthanized and tissues were processed for histology and
IHC.
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Tumor microarrays and IHC/immunofluorescence
ESCC tissue along with adjacent non-cancerous mucosa were obtained as surgical
biopsies from Kagoshima University Hospital, as described previously (37). The clinical
materials were obtained from informedconsent patients according to the Institutional
Review Board standards and guidelines. IHC and immunofluorescence were performed
as described previously (37). About 5 µM paraffin embedded sections were incubated
with WNT10A (Ab-106522, Abcam, Cambridge, MA 1:200) or WNT10A (SC-376028,
Santa Cruz Biotechnologies, Santa Cruz, CA 1:100). Immunofluorescence signal was
quantified in at least four independent high-powered fields per slide for mean intensity
using ImageJ (Schneider et al., 2012).
RNA isolation and quantitative PCR
Total RNA was isolated using GeneJet RNA Purification Kit (Thermo Fisher
Scientific, Waltham, MA) and cDNA was synthesized utilizing the Taqman Reverse
Transcription Reagents kit (Applied Biosystems, Foster City, CA) according to the
manufacturer’s instructions. Quantitative PCR was performed with primer sequences for
WNT10A Forward: 5′-ATCCACGAATGCCAACACCA-3′, Reverse: 5′CTCTCTCGGAAACCTCTGCT-3′ and ACTB Forward: 5′-CCTGGCACCC
AGGACAAT-3′, Reverse: 5′-GCCGAGCCACACGGAGTACT-3′ using Power SYBR
Green PCR Master Mix (PE, Applied Biosystems), according to manufacturer’s
instructions.
Western blotting
Proteins were separated through 4–12% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis Bis-Tris gel (Invitrogen) and then transferred to a poly membrane
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(Immobilon-P; Millipore, Billerica, MA). Membranes were then blocked with 5% non-fat
milk in TBS-T (1× TBS and 0.01% Tween-20), probed with primary antibody (1:500
WNT10A SC-376028, Santa Cruz, 1:1000 β-CATENIN D10A8, Cell Signaling, and
1:1000 GAPDH, Millipore) diluted in blocking buffer overnight at 4°C, washed with
TBST-T and incubated with horseradish peroxidase-coupled secondary antibodies (GE
Healthcare, Pittsburgh, PA). Signal was visualized with Amersham ECL-Prime (GE
Healthcare) as per manufacturer’s instructions.
Migration and invasion assays
Boyden chambers (8-µm pore size, FluoroBlok-HTS inserts; BD Biosciences, San
Jose, CA) were used for migration and invasion assays, as described previously (6). In
brief, Boyden chambers were coated with 200 µg/ml of Matrigel Matrix (BD
Biosciences) 2h before cell plating. Inserts were placed in a 24-well plate containing full
keratinocyte serum-free medium to stimulate cell migration and invasion. Cells (5×104 )
in keratinocyte basal media (Lonza, Basel, Switzerland) were placed in each insert.
Twenty-four hours later, migrating or invading cells were labeled with 4 µg/ml Calcein
AM dye (Invitrogen) in Hanks’ buffered salt solution buffer (Invitrogen) for 1h. Labeled
cells were then read on a Synergy HT multidetection microplate reader (BioTek,
Winooski, VT) at 485-nm excitation and 528-nm detection. Data represents the average
of three independent experiments performed in triplicate for each genotype.
Cell proliferation assay
A total of 3×103 cells were cultured in 96-well plates. Cell proliferation was
quantified using the WST-1 colorimetric assay (Roche, Penzberg, Germany) according to
manufacture’s instructions. Absorbance was measured on a microplate reader (Tecan
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Sunrise, Männedorf, Switzerland) at a wavelength of 450nm. Data represents the average
of five independent experiments performed in quintuplicate.
Flow cytometry and fluorescence-activated cell sorting
Flow cytometry was performed using LSRII (BD Biosciences) and FlowJo (Tree
Star, Ashland, OR). Cells were suspended in phosphate-buffered saline (Invitrogen)
containing 1% BSA (Sigma–Aldrich) and stained with PE/Cy7-anti-CD24 (1:40;
BioLegend, San Diego, CA) and APC-anti-CD44 (1:20; BD Biosciences) on ice for
30min. Flow cytometry data represent at least three independent experiments.
Self-renewal assays
About 100 cells were plated in single suspension in an ultra-low attachment 96
well-plate in 100 µl of mammary epithelial cell growth medium (Invitrogen). After
7 days, spheres were visualized and counted. All spheres consisted of greater than three
cells. Data represents three independent experiments performed in 96 replicates for each
cell type.
Statistics
Each experiment is presented as mean ± standard error (at least n=3) and was
analyzed by paired or non-paried two-tailed Student’s t-test. P < 0.05 was considered
significant. Overall survival curves were plotted by the Kaplan-Meier method and
subjected to the Log-rank and Gehan-Wilcoxon test. Chi-square test was used to
determine differences in proportion of WNT10A scoring in normal versus tumor samples.
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Figures and figure legends

	
   48	
  
	
  

Figure 1

Figure 1

Figure 1. WNT pathway is significantly upregulated in invasive mutant TP53 cells.
Ingenuity Pathway analysis shows networks of genes, known to be regulated by WNT
signaling in gene expression data, are significantly associated with TP53 mutations.
Upregulated and downregulated genes are indicated by red and green, respectively. The
lines and arrows represent functional and physical interactions and the directions of
regulation, as indicated in the literature.
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Figure 2. WNT10A is upregulated in invasive esophageal cells. (A) Representative
Hematoxylin and Eosin (H&E), WNT10A and DAPI staining of EPC2-hTERT-EGFRTP53R175H cells grown in 3-D organotypic culture (OTC). Non-invasive (NI) and
invasive (I) regions are delineated by white dots (B) Quantification utilizing ImageJ for
mean fluorescent intensity of WNT10A staining in the non-invasive versus invasive front
(n=4 independent experiments). Fluorescent intensity of invasive front is relative to noninvasive regions. Bar graphs represent relative mean ± SEM. **p<.005 (paired student’s
t-test) (C) qRT-PCR of WNT10A expression relative to ACTB comparing non-invasive
EPC2-hTERT-EGFR cells versus invasive EPC2-hTERT-EGFR-TP53R175H cells (n=3
experiments). Bar graph represents fold change ± SEM. **p<.005 (unpaired student’s ttest).
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Figure 3
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Figure 3. WNT10A promotes migration and invasion. (A) Western blot (cropped
image) of EPC2-hTERT-EGFR-p53R175H either overexpressing empty vector or
WNT10A. Multiple bands indicate post-translational modifications of WNT10A. Bcatenin densitometry indicates a modest 1.3-fold increase in total β-catenin relative to
GAPDH, with WNT10A overexpression (n=3 experiments). (B) Transwell Boyden
Chamber migration assay of Empty Vector compared to WNT10A cells along with
representative images of migratory cells stained with Calcein AM. (C) Transwell Boyden
Chamber invasion assay of Empty Vector compared to WNT10A cells with
representative images of invasive cells stained with Calcein AM. Scale bars =100 µM.
n=3 in triplicate. Bar graphs represent fold changes ± SEM. *p<.05, **p<.005 (paired
student’s t-test). (D) Proliferation assay utilizing a WST-1 colorimetric assay. (n= 5
experiments in quintuplicate). *p<.05 (paired student’s t-test).
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Fig. 4. WNT10A increases CD44High population and promotes self-renewal. (A)
Representative histograms of CD44 and CD24 levels between Empty Vector and
WNT10A cells, as expressed in a logarithmic scale. (B) Quantification of the
CD44High/CD24Low population between Empty Vector and WNT10A cells (n=3
experiments). Bar graphs represent fold change ± SEM within 3 different passages of
cells within one representative experiment. **p<.005 (unpaired student’s t-test). (C)
Quantification of the average number of spheres formed per well between Empty Vector
and WNT10A cells (n=3 experiments in 96 replicates). Bar graph represents fold change
± SEM. *p<.05 (paired student’s t-test). Representative images of the spheres from each
cell type indicate no difference in the size of the spheres formed. Each image was taken
at a magnification of x100.
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Figure 5

Figure 5. WNT10A is upregulated during esophageal development and in cancer.
(A) WNT10A IHC of embryonic (E12.5, E18.5), postnatal day 1 (P1), and adult
esophagus (E). Epithelial (e) and mesenchyme (m) are as indicated. (B) Representative
WNT10A staining in esophagus of control mice versus mice treated with 10mg/ml of 4NQO for 16 weeks. Downward growths and hyperplasia/dysplasia are indicative of early
ESCC. Bar graph represents average scoring of esophagi ± SEM. *P < 0.05 (unpaired
Student’s t-test) of three control and five experimental mice. (C) Western blot (cropped
image) for WNT10A on a panel of ESCC human cell lines, as compared to normal,
immortalized epithelial cells (EPC2-hTERT).
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Figure 5

Figure 5. WNT10A is upregulated during esophageal development and in cancer.
(D) Representative images of WNT10A scoring classifications of adjacent normal (upper
left panel) versus carcinoma in situ (CIS), and tumor tissue. Scoring was based on
cytoplasmic intensity (Cy0, Cy1, Cy2, and Cy3). All scale bars are 100µM. (E) Scoring
stratified between low staining intensity (Cy0 and Cy1) and high staining intensity (Cy2
and Cy3) WNT10A staining between normal adjacent tissue and tumor sections,
respectively (red square box). p<.0001 (Chi-square test).
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Figure 5

Figure 5. WNT10A is upregulated during esophageal development and in cancer.
(F) Kaplan-Meyer survival curve of tumor staining stratified between low WNT10A
staining intensity versus high WNT10A staining intensity, with median survival time
(MST).
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Supplementary Table 1:
Ingenuity Canonical Pathways

P-values

Molecules

Cell Cycle Control of Chromosomal Replication

5.88844E-07

Mitotic Roles of Polo-Like Kinase
Regulation of Cellular Mechanics by Calpain
Protease

1.23027E-05

CDC7,MCM2,MCM6,MCM4,MCM5,CDC6
CDC7,PRC1,PLK4,CDC20,HSP90AB1,CCNB1,CDC
27

0.000549541

CAPN3,CNGB1,TLN1,CCNA2,ACTN1

VDR/RXR Activation

0.002238721

KLK6,IGFBP3,CALB1,CSNK2A1,IGFBP6

Cyclins and Cell Cycle Regulation

0.002238721

CCND2,CCNA2,HDAC4,HDAC9,CCNB1

Role of IL-17A in Arthritis

0.003715352

CCL7,CCL2,PIK3C2B,CXCL5

IGF-1 Signaling

0.005754399

SOCS3,PIK3C2B,IGFBP3,CSNK2A1,IGFBP6

p53 Signaling
Regulation of the Epithelial-Mesenchymal
Transition Pathway

0.006025596

CCND2,BIRC5,PIK3C2B,ADCK3,HDAC9
WNT10A,PARD6B,WNT5B,PIK3C2B,EGR1,JAG,
HGF

Eicosanoid Signaling

0.006456542

ALOX15B,RARRES3,PLA2G4F,PTGES

Paxillin Signaling

0.007079458

TLN1,PIK3C2B,ITGB8,PARVA,ACTN1

IL-17A Signaling in Fibroblasts

0.007943282

CCL7,CCL2,CXCL5

BER pathway

0.008317638

FEN1,LIG1

Role of IL-17A in Psoriasis

0.009772372

S100A7,CXCL5
CAPN3,TLN1,PIK3C2B,ITGB8,PARVA,ACTN1,AR
PC1B

Integrin Signaling

0.00616595

0.01

IL-17 Signaling
Role of IL-17F in Allergic Inflammatory Airway
Diseases

0.01023293
0.014791084

CCL7,CCL2,CXCL5

Atherosclerosis Signaling

0.015135612

MMP3,CCL2,ALOX15B,RARRES3,PLA2G4F

GADD45 Signaling

0.020417379

CCND2,CCNB1

Human Embryonic Stem Cell Pluripotency

0.020892961

WNT10A,WNT5B,PIK3C2B,SOX2,BDNF

Insulin Receptor Signaling

0.020892961

PPP1R3D,PPP1R14A,SOCS3,PIK3C2B,GYS2

L-glutamine Biosynthesis II (tRNA-dependent)

0.023442288

GATB

Chronic Myeloid Leukemia Signaling

0.023988329

MECOM,PIK3C2B,HDAC4,HDAC9

CDK5 Signaling

0.029512092

PPP1R3D,PPP1R14A,EGR1,BDNF

Telomerase Signaling

0.029512092

PIK3C2B,HDAC4,HSP90AB1,HDAC9

Ascorbate Recycling (Cytosolic)

0.034673685

GLRX

Glutathione Redox Reactions II

0.034673685

GLRX

4-aminobutyrate Degradation I

0.034673685

ALDH5A1

Cell Cycle: G1/S Checkpoint Regulation
Role of NANOG in Mammalian Embryonic Stem
Cell Pluripotency
Role of MAPK Signaling in the Pathogenesis of
Influenza

0.039810717

CCND2,HDAC4,HDAC9

0.041686938

WNT10A,WNT5B,PIK3C2B,SOX2

0.045708819

CCL2,RARRES3,PLA2G4F

GDNF Family Ligand-Receptor Interactions

0.045708819

NRTN,PDLIM7,PIK3C2B

Remodeling of Epithelial Adherens Junctions

0.045708819

ACTN1,HGF,ARPC1B

Macropinocytosis Signaling

0.045708819

PIK3C2B,ITGB8,HGF

Hereditary Breast Cancer Signaling

0.046773514

PIK3C2B,HDAC4,HDAC9,CCNB1

Growth Hormone Signaling

0.047863009

SOCS3,PIK3C2B,IGFBP3

Wnt/Î²-catenin Signaling

0.048977882

WNT10A,WNT5B,DKK1,SOX2,CSNK2A1
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MMP3,CCL2,PIK3C2B,CXCL5

Supplementary Table 1. Significantly upregulated pathways associated with
invasive mutant TP53 gene signature. Upregulated pathways associated with invasive
TP53 mutant (R175H, R248W, R273H, V143A) gene signature P-values (Fisher’s exact
test) estimate the statistical significance of the overlap between the dataset genes and
genes regulated by the regulator. Bolded boxes indicate upregulated pathways associated
with WNT10A
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CHAPTER 3: The role of mutant TP53 in the development of a mouse model of
esophageal squamous cell carcinoma
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Abstract
Wild-type TP53, a potent tumor suppressor gene, is responsible for initiating
appropriate responses to a variety of cellular stresses and is the most commonly mutated
gene in human cancers. Strikingly, most TP53 mutations are missense mutations within
one of six hotspot codons in the DNA-binding domain (DBD). Recent evidence suggests
that the DBD mutants can confer neomorphic activity or act as gain-of-function (GOF)
mutants, in order to promote tumor progression. Over 80% of esophageal squamous cell
carcinomas (ESCC) contain TP53 mutation, with the majority within the DBD. Major
risk factors of ESCC include smoking, alcohol use, and factors that induce tissue stress,
such as irradiation and caustic injury of the esophagus. In order to determine how TP53
mutation affects the progression of ESCC, we developed a mouse model of ESCC, which
is driven by an esophageal specific Cre-recombinase, in order to induce Tp53 mutation,
and a chemical mutagen, 4-Nitroquinoline 1-oxide (4NQO). Mice are additionally lineage
labeled with an YFP+ allele, to allow for detection of recombined cancer cells in
metastatic sites, such as lymph nodes and lung. We found that mutation in Tp53 (R172H)
significantly accelerates initiation and progression of ESCC by 4 to 6 weeks, as compared
to total Tp53 loss. This finding suggests that mutant TP53 can promote tumorigenesis in a
GOF mechanism. Furthermore, in order to further elucidate the role of Tp53 mutation in
ESCC, we performed RNA-seq on established cancer cell lines from mouse tumors, with
or without TP53 mutation or loss. Our preliminary findings suggest mutant TP53 may
promote an epithelial to mesenchymal transition (EMT) gene signature, leading to a
potential GOF role of mutant TP53 in ESCC metastases.
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Introduction
Esophageal squamous cell carcinoma (ESCC) is one of the deadliest tumor types
due to its highly invasive and early infiltrative nature (Altekruse et al., 2009). It is
characterized by high-grade dysplasia of the epithelial layers with invasion into the
lamina propria and potential extension into the muscle layers and surrounding tissue,
depending on tumor grade (Taylor et al., 2013). Major risk factors of certain etiologies of
ESCC include smoking and alcohol use (Toh et al., 2010). Additionally, it is one of the
cancers with the highest rate of TP53 mutation, suggesting that TP53 mutation may be a
driver of carcinogenesis.
Our lab has previously described an in vitro role of mutant TP53 in ESCC. When
primary epithelial immortalized cells overexpress mutant TP53 in conjunction with
Epidermal Growth Factor Receptor (EGFR) overexpression, they develop enhanced
proliferative, migratory, invasive and colony formation capabilities (Okawa et al., 2007).
More specifically, these cells can induce invasion in an in vivo-like system of 3D
organotyipc

culture

(OTC),

with

cellular

protrusions

into

the

underlying

fibroblast/matrigel/collagen support layer (Michaylira et al., 2010; Kalabis et al., 2012).
Incidentally, different hotspot DNA binding domain (DBD) mutations of TP53 exhibited
different tumorigenic properties in the cell culture model of esophageal cancer, with the
conformation-altering mutant R175H being the most invasive (Michaylira et al., 2010).
These hotspot mutants have previously been suggested to confer gain-of-function (GOF)
or neomorphic properties to induce additional oncogenic capabilities in cancer cells.

	
   61	
  
	
  

In order to better elucidate the mechanisms by which mutant TP53 may be
promoting ESCC, we chose to generate an in vivo mouse model of ESCC driven by the
R172H mutation (mouse orthologue of human R175H). Indeed, previous mouse models
of ESCC have been derived, through other mechanisms, which will be briefly discussed
below.
(1) Namely, the fastest and most highly penetrant model of mouse ESCC utilizes
4-nitroquinoline 1-oxide (4-NQO) in the drinking water. 4-NQO is a carcinogen that can
induce bulky adducts in DNA, as well as DNA breaks, similar to cigarette smoke. Mice
are administered 4NQO in their drinking water for an initial 16-week period with an
additional 12-week wash out period. After the end of the 28-week experimental period,
mice on 4NQO develop 100% penetrance of hyperplasia, papilloma, and invasive
carcinoma. A caveat of this model is its stochastic nature, which is purely carcinogen
driven (Tang et al., 2004).
(2) Concurrent loss of E-CADHERIN and Transforming Growth Factor Betareceptor II (TGFBR2) in vitro has also proven to induce invasion of esophageal cancer
cells in vitro (Andl et al., 2006). When these genes were deleted in mice with the L2
promoter driven Cre recombinase (L2-Cre), which is specific for the oral squamous,
ventral tongue, esophageal, and forestomach, there was development of oral squamous
cell carcinoma over a period of 18 months. Notably though, these mice also demonstrated
metastasis in lymph node and lung tissue (Nakagawa et al., 1997; Andl et al., 2014).
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(3) SOX2 is a driver of proliferation and stratification of the esophageal lineage in
development (Que et al., 2007). Furthermore, its re-expression has been shown to be
prominent in various squamous cell cancer types, especially in ESCC. When SOX2
overexpression is induced by the Keratin 5 (Krt5) promoter, which is specific for the
basal layer of the epidermis and aerodigestive tract, mice develop carcinomas in the
forestomach over the period of 5 months. These carcinomas display increased nuclear
STAT3 localization, which suggest an inflammatory component requirement in the
development of carcinoma. Only when SOX2 is overexpressed concomitantly with
nuclear STAT3, can esophageal carcinoma develop. Limitations of this model include the
localization of the carcinoma, which is not esophageal specific and the dermatitis
development in these mice, due to expression of Krt5 in the basal layer of the epidermis,
as well (Liu et al., 2013).
(4) Another inflammatory driven model of esophageal cancer utilizes deletion of
Ctnnb2 (p120 CATENIN). In human ESCC samples, p120 CATENIN has been
demonstrated to be either lost or mislocalized away from the cell membrane, where it
would normally tether E-CADHERIN. Interestingly, when p120 CATENIN was deleted
with the L2-Cre recombinase, not only did E-CADHERIN appreciably decrease but there
was additionally increased expression of nuclear NF-KAPPAB. Over the course of 8 to
12 months, these mice developed dysplasia and invasive carcinoma of the oral tissue,
esophagus and forestomach. Treatment of these mice with dexamethasone, led to a
decrease in the proliferation and tumor invasion, suggesting that inflammation can also
drive esophageal carcinogenesis (Stairs et al., 2011).
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Taken together, we decided to utilize genetic and environmental components, in
order to generate a model of murine ESCC. We chose a common mutation of TP53 in
humans, as the R175H mutant accounts for 6% of all TP53 mutations in ESCC and
utilization of 4-NQO, as it can accelerate the progression of ESCC in mice. Additionally,
we chose to utilize the L2-Cre recombinase, as it is most specific for esophageal tissue.
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Results
Generation of a mouse model of ESCC.
We utilized mice that had a knock-in mutation at the R172H codon of Tp53
(Olive et al., 2004). By crossing these knock-in mutants to mice with a L2-Cre
recombinase transgene and additional floxed alleles surrounding the Tp53 loci, we were
able to generate compound Tp53 mutant mice, specifically in the oral squamous,
esophageal, and forestomach tissues (Nakagawa et al., 1997; Marino et al., 2000).
Ultimately, we generated five different combinations of genotypes at the Tp53 loci: +/+,
+/-, R172H/+, -/- , and R172H/-. Additionally, we crossed in at least one copy of the R26stop-EYFP allele to each mouse. This allele allows expression of the EYFP gene at the
Gt(Rosa)26Sor loci when a Cre-recombinase is expressed to delete the lox-p flanked
STOP sequence, thus allowing lineage labeling of all recombined cells. At 8-12 weeks of
age, mice were subjected to treatment of 10 mg/mL 4-NQO ad libitum in their drinking
water for 16 weeks and then euthanized (Figure 1A).
Initial histology of the esophagus of these mice showed varying degrees of
hyperplasia, dysplasia, downward growths, micro invasion, and frank invasive squamous
cell carcinoma, depending on genotype. In TP53+/+ control mice, the predominant
features of the esophagi were hyperproliferation of the basal layer and a mild
inflammatory response (Figure 1B). When one allele of Tp53 was lost, TP53+/- mice
exhibited increase in basal layer proliferation along with dysplastic features of suprabasal
layer. Downward growths can also initially be seen (Figure 1C). In TP53R172H/+ mice,
increased dysplasia and inflammation is seen, with signs of microinvasion into the
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underlying lamina propria (Figure 1D). TP53-/- mice, herein known as TP53 null mice,
displayed variability in phenotype between microinvasion and invasive squamous cell
carcinoma (Figure 1E). Lastly, TP53R172H/- mice, herein known as compound mutants,
displayed thickened esophagi with macroscopic tumors, causing food impaction (data not
shown) and invasive squamous cell carcinoma to both the lamina propria and surrounding
muscle layers (Figures F and G).
TP53 immunohistochemistry staining was confirmed in the null mice and the
compound mutants (Figures 1H-J). No antibody control (Figure 1H) displayed no TP53
staining, and TP53 null mice exhibited either low levels or no nuclear staining. Positive
nuclear TP53 staining in the TP53 null histological samples may signify immune
infiltrates, which maintain two wildtype copies of the Tp53 gene (Figure 1I). Compound
mutant mice exhibited high levels of TP53 nuclear staining both in the epithelial layer as
well as underlying stroma and muscle layers, indicative of invasive epithelial cells. TP53
staining was performed on TP53+/+, TP53+/- and TP53R172H/+ mice and showed
intermediate levels of nuclear TP53 staining, indicative of either active wildtype or
mutant TP53, as the two alleles are indistinguishable based on IHC staining (data not
shown). YFP expression was also confirmed by a fluorescent microscope, as a marker of
recombination (Figure 1K-L), indicating strongest fluorescence in tumor tissue.
Mutant TP53 may decrease tumor latency
Having established a mutant TP53 driven mouse model of ESCC, but with
varying histological patterns, we next wanted to determine if there were differences
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amongst the different genotypes of mice. We additionally wanted to determine if the
TP53R172H mutation could confer GOF properties over the null allele. In order to examine
tumor latency, we chose to treat all experimental mice with the same 16 weeks of 4-NQO
in the drinking water ad libitum but additionally included a washout period. During the
16-week treatment period as well as the 12-weeks following, we carefully monitored
mice for signs of distress and significant weight loss (Figure 2A).
When mice displayed signs of illness, they were euthanized and examined grossly
and via histology for invasive squamous cell carcinoma, and we plotted tumor incidence
at specific time points for each genotype (Figures 2B and 2C). When sick mice were
euthanized and found not to contain an esophageal tumor, these mice were marked as
only censored at that particular time point. We firstly compared the tumor incidence
curves between the TP53R172H/+ and TP53+/- mice, which would allow us to compare the
effects of a TP53R172H allele versus the null allele when one wildtype copy of Tp53 is till
present (Figure 2B). In effect, we saw no difference between these two curves in terms of
tumor incidence. Additionally, the TP53R172H/+ and TP53+/- mice had median tumor
incidence of 24.5 weeks and 23 weeks respectively. We next compared directly the
compound mutant mice the null mice. There was a significant difference in terms of their
tumor incidence curves (Gehan-Breslow-Wilcoxon test p=.0470) (Figure 2C).
Additionally, the median survival time between both of these groups were shorter
compared to the TP53R172H/+ and TP53+/- group; the compound mice and null mice had a
median tumor incidence time of 18 weeks and 22 weeks, respectively. Wildtype mice
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treated with 4-NQO were also monitored, but these mice did not begin developing tumors
until 14 to 16 weeks after the washout period begin (Data not shown).
Interestingly, during the 12-week washout period, mice of all genotypes began
developing metastases to adjacent lymph nodes as well as micrometastases to the lungs.
Lymph nodes were dissected out and examined under the fluorescent microscope and
determined to be YFP+, indicating epithelial origin (Figure 2D and E). Additionally,
histologically, dysplastic epithelial cells can be found in the lymph node. Lung tissue also
showed signs of micrometastases by histology (Figure 2F). These findings suggest that
TP53 mutation or loss in concert with 4-NQO treatment can induce a metastatic model of
ESCC in mice.
Mutant TP53 may confer an epithelial-mesenchymal transition (EMT) signature
To further dissect out the GOF role of mutant TP53 in ESCC, we generated cell
lines from the tumors of both the null and compound mutant mice in order to perform ex
vivo experiments. In these initial experiments, we were able to generate two different
TP53 compound mutant cell lines and one null cell line. Cell lines were further confirmed
to express YFP (Figure 3A), to exclude contaminating, non-esophageal epithelial cells.
Furthermore, TP53 was shown to be stabilized and highly upregulated in both compound
mutant cell lines but not expressed in the null cell lines (Figure 3B).
In order to determine the transcriptional profile of these cells, we performed
RNA-seq in duplicate for each of these cell lines, along with a wildtype mouse
esophageal cell line control. Reads were adjusted to sequencing read depth and then
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quantile normalized. Fold change was determined as compared to the wildtype cells.
Classic wildtype TP53 targets such as Mdm2 and Cdkn1A were downregulated in the
compound mutant and null cells (data not shown). Since the TP53 null cells were also
tumor derived, many expression changes could be attributed to the transformation
process. Differences between the compound mutants versus the null cells may be
attributed to direct and indirect functions of mutant TP53, although stochastic carcinogen
induced events cannot be entirely excluded.
Interestingly, preliminary analysis of the RNA-seq data show an increase in
expression of mesenchymal genes in the compound mutant cells, as compared to both the
null cells and wildtype cells, along with a decrease in epithelial genes. Pathway analysis
additionally indicated epithelial to mesenchymal transition (EMT) as the most
statistically significant pathway dysregulated in both compound mutant cells, as
compared to the null cells (data not shown). EMT is critical in development and wound
healing but can also become co-opted during tumorigenesis to induce invasion and
metastasis. During EMT, epithelial cells lose junctions and change cellular shape; the
classic change of EMT includes loss of Cdh1 (E-cadherin) and gain of Cdh2 (Ncadherin). Expression changes in Twist, Zeb1/2, Snail, Sparc, Vimentin, which have all
previously been suggested of supporting mesenchymal phenotypes (Thiery et al., 2009;
Lamouille et al., 2014; Vannier et al., 2013) are shown to be upregulated in the
compound mutant cells. Correspondingly, the compound mutant cells exhibit a decrease
in expression of genes associated with the epithelial phenotype, such as Cdh2 and Epcam,
as compared to the TP53 null cells and wildtype control. Furthermore, Ctnnb2, the gene,
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which encodes for the protein p120 CATENIN is highly down regulated in mutant
compound cells. Keratins, which are associated with esophageal keratinocytes, such as
Krt4 and Krt8 are additionally downregulated in the compound mutants, suggesting a loss
of epithelial identity.
Although many of these gene targets need to be confirmed, there is indeed a trend
toward EMT induction in the compound mutant cells. Since EMT may be critical for
tumor cell dissemination and extravasation, future experiments will focus on the ability
of compound mutant cells to induce metastases in a retro-orbital injection model of lung
metastasis. In order to perform these experiments utilizing isogenic controls, we knocked
down mutant Tp53 in both compound mutant cell lines with two different short hairpins
against mouse Tp53 (Figure 3C). These cells will be utilized for future experiments to
examine the role of mutant TP53 in EMT, mesenchymal to epithelial transition (MET)
and metastasis.
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Discussion
We have demonstrated that mutations in TP53, in conjunction with a 16-week
regiment of 4-NQO in the drinking water, can lead to high-grade dysplasia and induction
of invasive squamous cell carcinoma. Based on our tumor incidence curves, we observe
(1) TP53 null and compound TP53 mutants demonstrate a decreased median tumor
latency time, as compared to their heterozygote controls, and (2) TP53 compound mice
display the fastest tumor latency as compared to all other genotypes. This first finding
supports the notion that a wildtype copy of Tp53 can delay the onset of tumorigenesis,
similar to patients who exhibit germ-line mutations of Tp53 at one allele (Malkin et al.,
1990). Although we have not yet sequenced the tumors from the heterozygote mice, we
expect that loss of heterozygosity at the Tp53 loci would be necessary for full
transformation of the tissue, as previously reported (Olive et al., 2004) Furthermore, our
data suggest that there is no statistical difference in tumor incidence curves between
mutant TP53 and loss of TP5 when a wildtype allele is still present.
The second finding suggests that mutant TP53 may have oncogenic functions in
order to induce faster progression of ESCC as compared to loss of TP53 alone. Previous
mouse models of mutant TP53 driven carcinomas have demonstrated varied results on the
role of mutant TP53 versus loss of TP53 alone during tumor progression. Global
compound TP53 mutant mice, with the R172H allele, compared to TP53 null mice
showed no difference in tumor latency, but rather, showed either a difference in tumor
spectrum or increase in metastases potential in the TP53 compound mice (Olive et al.,
2004; Lang et al., 2004). In a mammary tumor model, driven by overexpression of WNT	
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1, addition of a humanized R175H knock-in mutation of TP53 did not potentiate faster
tumorigenesis as compared to addition of loss of TP53. Yet the mutant compound mice
exhibited increased number of mammary tumors as compared to the null controls (Lu et
al., 2013). Interestingly though, in an APCfl/+ model of intestinal carcinoma, addition of a
TP53R172H/+ allele in mice led to significant increase in invasive tumors, as compared with
the addition of a TP53+/- allele, with no difference in overall survival (Muller et al., 2009).
Although our results are currently not powered to make definitive conclusions on
the role of mutant TP53 in tumor induction and progression, we find further evidence to
suggest that mutant TP53 may play an oncogenic roles in inducing EMT, based on our ex
vivo RNA-seq results. Incidentally, wildtype TP53 can repress EMT through multiple
mechanisms. Loss of TP53 has been shown to downregulate miR-200c, leading to an
induction of an EMT program, with increases in levels of N-CADHERIN and ZEB1
(Chang et al., 2011). TP53 can also repress the expression of SLUG, through its
downstream target, MDM2. Slug, in turn, can promote EMT through its regulation of ECADHERIN and MMP-2 (Wang et al., 2009).
Yet, in our dataset, many EMT associated genes are further deregulated in the
TP53 compound mutant cells as compared to the TP53 null cells, suggesting additional
roles of mutant TP53. Previous notions of GOF mutant TP53 in EMT and invasion have
been reported. In prostate cancer cell lines, the R175H mutant has been shown to
upregulate TWIST by alleviating repressive marks at the promoter (Kogan-Sakin et al.,
2011). Several works have additionally highlighted the role of mutant TP53 in the
inactivation of various isoforms of TP53 family members, TP63 and TP73, in order to
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induce invasion. Inhibition of TAp63 through binding at the DBD by mutant TP53, leads
to inhibition of integrin and EGFR recycling, and thus a more invasive phenotype (Muller
et al., 2009). Moreover, TGF-β was shown to stabilize the interactions of mutant TP53
and TP63, leading to downregulation of the TP63 targets, SHARP-1 and CCNG2, and
cellular migration (Adorno et al., 2009). Finally, in pancreatic cancer, mutant TP53 can
inhibit the TP73/NFY repression of PDGFRB, in order to promote invasion and
metastasis (Weissmueller et al., 2014).
Incidentally, our dataset did not indicate any changes in expression of Tp63 or
Tp73, at least not in the RNA-level. However, we do observe marked increases in
multiple mesenchymal transcription factors such as Zeb1/2, Twist1 and Snail. In addition
to regulation of one another, these transcription factors can work both alone and in
concert in order to induce repression CDH1 and activation of CDH2 (Montserrat et al.,
2011). Our RNA-seq data, in agreement, show that in the compound mutant cells, there is
indeed a cadherin switch, with downregulation of CDH1 to upregulation of CDH2.
VIMENTIN, a major cytoskeletal feature of mesenchymal cells, is additionally
upregulated. Correspondingly, the compound mutant cells lose epithelial identity through
the downregulation of basal and suprabasal keratins, K14 and K4, respectively.
In ESCC, EMT can be promoted through various potential mechanisms. One of
the most potent methods of EMT induction is through TGF-β signaling (Mani et al.,
2008; Ohashi et al., 2010b). Within a 14-day TGF- β treatment, both transformed
epithelial cells and esophageal cancer cells can induce an E-CADHERIN to NCADHERIN switch, along with induction of ZEB1/2, and acquisition of a spindle shaped
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morphology (Ohashi et al., 2010b). NOTCH3 can inhibit the TGF- β mediated changes,
whereas reactive oxidative species may promote the EMT (Ohashi et al., 2011; Kinugasa
et al., 2015). Of note, the cells that undergo EMT, additionally shift cell surface marker
expression to a CD44High- CD24Low population (Ohashi et al., 2010a; Mani et al., 2008).
These markers have previously been implicated as putative cancer stem cell markers. Our
RNA-seq data set do not indicate a strong inclination towards increased Cd44 expression
in the compound mutant cells, although we do see a marked decreased in Cd24
expression. Yet, Cd44 induction may be regulated at the protein level, and thus it would
be of interest to investigate the protein expression of CD44 in the compound mutant cells
as compared to null cells through fluorescence-activated cell sorting-analysis. In addition
to promoting metastases and potentially cancer stem cell-like phenotypes, EMT can also
induce increased tumor budding in ESCC. Tumor budding, which is a poor prognostic
marker in ESCC, describes isolated cells out side the margin of a tumor and is associated
with high levels of VIMENTIN and low levels of E-CADHERIN (Niwa et al., 2014).
Future directions will focus on the effect of mutant TP53 on EMT, invasion, and
metastasis. In addition to generating more tumor-derived cell lines of both compound
mutant TP53 cells and TP53 null cells, we will perform quantitative PCR to validate the
EMT gene signature derived from our RNA-seq. Since EMT has also been associated
with a more stem-like phenotype, we will also determine if changes in stemness markers
are affected in the compound mutant TP53 cells at the protein level, as we did not detect
changes in the RNA-level (Mani et al., 2008). These acquired stemness properties by
EMT cells are also critical for survival during the extravasation process, and eventual
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metastasis. We will functionally test if compound mutant TP53 cells can produce
metastasis in a retrooribtal injection model of lung metastasis. Knockdown of mutant
TP53 has been previously reported to decrease metastatic potential to both the lung and
liver in a pancreatic cancer model (Weissmueller et al., 2014). Our experiments will
validate the potentially crucial role of mutant TP53 in mediating EMT, metastasis and
overall poorer survival in ESCC.
Finally, we plan to mechanistically decipher the role of mutant TP53 in ESCC,
and determine if mutant TP53 affects EMT-associated genes in a direct or indirect
manner. We will perform a ChIP-seq for mutant TP53 in the compound mutant cell lines.
Since, wildtype TP53 is deleted through recombination, we would specifically be
immunonopercipitating for mutant TP53. This data set in combination with our RNA-seq
results could indicate future direct targets of mutant TP53, and its potential GOF
properties.
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Materials and methods
Generation of mouse model
The Institutional Animal Care and Use Committee (IACUC) at the University of
Pennsylvania approved all animal studies. L2-Cre transgenic mice were generated by
cloning Cre recombinase under the control of the EBV ED-L2 promoter (Nakagawa et
al., 1997; Opitz et al., 2002) and were genotyped as previously described (Stairs et al.,
2011). TP53R17H, TP53fl and RosaYFP mice have previously been described (Olive et al.,
2004; Marino et al., 2000; Srinivas et al., 2001). 4-nitroquinoline 1-oxide (4-NQO)
experiments were performed as described previously (Tang et al., 2004; Long et al.,
2015). In brief, 8 to 12-week-old mixed background mice, bearing the L2-Cre, Tp53
mutant and/or wildtype alleles, and YFP transgene were given 10mg/ml of 4-NQO
diluted in 10% propylene glycol in their drinking water ad libitum. Mice were euthanized
either directly after 16-weeks of treatment or during the 12-week wash out period.
Tissues were processed for histology and immunohistochemistry (IHC) or cell lines were
generated from the tumor tissue.
Histology and immunohistochemistry (IHC)
Tumor tissue were embedded in paraffin blocks and cut in 5 µM sections.
Hematoxlyin and eosin (H&E) and IHC staining were performed as previously described
(Long et al., 2015). All histology was read blinded by an independent pathologist.
Paraffin embedded sections were incubated with mouse TP53 antibody (CM5, Vector
Labs, Burlingame, CA 1:250).
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Cell isolation and culture
Tumor derived cancer cells were generated as previously described (Stairs et al.,
2011). In brief, freshly isolated esophageal tumors were digested in dispase (Thermo
Fisher Scientific, Waltham, MA) for 10 minutes at 37° on a shaker. Esophagi tumors
epithelial cells were then peeled from the submucosa and subjected to incubation in
trypsin-EDTA (Thermo Fisher Scientific) for 10 minutes at 37° on a shaker. Detached
cells were filtered through a 40 µM strainer into soybean trypsin inhibitor (Thermo Fisher
Scientific). Cells were then centrifuged and resuspended and plated in calcium-free
keratinocyte serum-free media (Invitrogen, Carlsbad, CA), supplemented with 40 µg/ml
of bovine pituitary extract, 1ng/ml epidermal growth factor, 18 µM of CaCl2, and 1%
penicillin/streptomycin. Short hairpins against murine TP53, cloned into the pLKO.1
vector were a gift from Dr. Berger. Lentiviral spinfection was performed as described
previously on cultured tumor cell lines (Michaylira et al., 2010). Lentiviral infected cells
were selected in 2 µg/mL of puromycin. Knockdown was confirmed via western blot.
RNA isolation and sequencing
Cells were grown to 80% confluency in 10 cm dishes. Cells were harvested and
polyA+ mRNA was isolated by double selection with mRNA Direct Dynabeads
(Invitrogen). PolyA+ mRNA were fragmented to an average size of 200bp using Mg2+containing buffers at 94˚C for 15 minutes. First-strand synthesis was performed using
Protoscript II reverse transcriptase and random hexamer primers (New England Biolabs,
Ipswich, MA). Directional second-strand synthesis was performed using the dUTP
method (New England Biolabs). End-repair, adapter ligation, and 12 cycles of PCR were
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performed as per the NEBnext Ultra protocol to produce barcoded, Illumina-compatible
sequencing libraries. Insert size distribution was measured using the Agilent Bioanalyzer
(Agilent Technologies, Santa Clara, CA) and sequencing library molarity was quantified
by the Kapa method using absolute quantification standards. Reads were mapped as
previously described (Sammons et al., 2015). Relative reads were normalized to the
wildtype cell line.
Western blot
To confirm protein expression, western blotting was performed as previously
described (Long et al., 2015). Proteins were separated through a 4–12% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis Bis-Tris gel (Invitrogen) and transferred to a
polyvinylidene difluoride membrane (Immobilon-P; Millipore, Billerica, MA).
Membranes were blocked with 5% non-fat milk in TBS-T (1× TBS and 0.01% Tween20), probed with primary antibody (1:1000 TP53 CM5, Vector Labs, 1:1000 GAPDH,
Millipore), diluted in blocking buffer overnight at 4°C, washed with TBST-T and
incubated with horseradish peroxidase-coupled secondary antibodies (GE Healthcare,
Pittsburgh, PA). Signal was visualized with Amersham ECL-Prime (GE Healthcare) as
per manufacturer’s instructions.
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Figures and figure legends
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Figure 1
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Figure 1. Mutations in TP53 with 4-NQO can induce dysplasia and invasive
squamous carcinoma of the esophagus (A) Schematic of experimental treatment plan
indicating genotypes of mice and time period of 4-NQO treatment. (B-G) Representative
Hematoxylin and Eosin (H&E) images of the esophagus after 16-weeks of 4-NQO
treatment in (B) TP53+/+ (C) TP53+/- (D) TP53R172H/+ (E) TP53-/- (F-G) TP53R172H/- mice.
Scale bars represent 100 µM.
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Figure 1
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Figure 1. Mutations in TP53 with 4-NQO can induce dysplasia and invasive
squamous carcinoma of the esophagus. (H-J) Representative TP53 staining of mouse
tumors. (H) No antibody control (I) staining in a TP53-/- tumor and (J) staining in a
TP53R172H/- tumor. Bars represent 100 µM (K-L) Representative images of esophageal
tumors in (K) brightfield and with (L) YFP filter. Bars represent 5 mM.
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Figure 2

A

B

C

Tumor Incidenc e

100

100

R172H/- n=12
-/- n=7

R172H/+ n=8
-/+ n=7
50

50

0

Tumor Incidenc e

0
0

10

20

30

40

0

10

20

We e ks Elapsed

We e ks Elapsed

Figure 2. Mutations in TP53 with 4-NQO can lead to invasive squamous carcinoma
of the esophagus and metastasis to the lymph node and lung (A) Schematic of
experimental treatment plan indicating genotypes of mice and time period of 4-NQO
treatment along with washout period with normal drinking water. (B-C) Tumor incidence
curves of (B) TP53-/+ and TP53R172H/+ mice and (C) TP53-/- and TP53R172H/- mice. No
statistical difference is seen in tumor incidence between TP53-/+ and TP53R172H/+ mice.
Difference in tumor incidence curve between TP53-/- and TP53R172H/- mice is statistically
significant based on Gehan–Breslow–Wilcoxon test (P= 0.04).
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Figure 2. Mutations in TP53 with 4-NQO can lead to invasive squamous carcinoma
of the esophagus and metastasis to the lymph node and lung. (D-F) Representative
images of lymph nodes from tumor-burdened mice in (D) bright field (E) YFP-filter and
(F) H&E stained. (G) Representative H&E of micrometastsis of squamous cell carcinoma
in lung parenchyma. Bars in (D-E) represent 5 mM and (F-G) represent 10 µM.
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Figure 3
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Figure 3. Isolation of cells from mouse tumors. (A) Representative images of cells
isolated from an TP53R172H/- tumor, which displays a mix of epithelial and spindle-shaped
morphology. Brightfield and YFP filtered images are shown at x200. (B) Western blot for
TP53 (1:1000, CM5) and GAPDH (1:1000) in two different TP53R172H/- cell lines and one
TP53-/- cell line. (C) Western blot for TP53 and GAPDH after lentiviral transduction of
pLKO.1 shSCR or shp53 constructs were stably expressed in both TP53R172H/- cell lines.
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Table 1

Mesenchymal	
  
Genes	
  
Gene	
  
Cdh2	
  
Itga5	
  
Serpine1	
  
Slug	
  
Snail	
  
Sparc	
  
Twist1	
  
Twist2	
  
Vimentin	
  
Zeb1	
  
Zeb2	
  

	
  	
  
R172H/-‐	
  (1)	
  
59.81751582	
  
1.595422603	
  
1.444222711	
  
1.049709519	
  
105.1897074	
  
19.49080083	
  
1.721886975	
  
2.753315833	
  
1429.164941	
  
51.68922707	
  
9.869476577	
  

	
  	
  
R172H/-‐	
  (2)	
  
49.93173493	
  
0.807512798	
  
4.071795564	
  
0.845504489	
  
2.328456105	
  
28.36893606	
  
2.645723427	
  
12.92097264	
  
3116.429364	
  
84.34181017	
  
6.45025041	
  

	
  	
  
	
  	
  
-‐/-‐	
  
+/+	
  
3.444777445	
  
0.695034127	
  
4.117733044	
  
1	
  
1.625126135	
  
7.4036831	
  
0.891134343	
  
8.604172423	
  
281.908284	
  
6.646976372	
  
1.243385188	
  

Table 1: Genes associated with a mesenchymal gene signature. Genes that are highly
upregulated in the TP53R172H/- samples as compared to both the TP53-/- and TP53+/+ cells
are hi-lighted in green. All values are expressed as fold change over reads in TP53+/+
cells.
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1	
  
1	
  
1	
  
1	
  
1	
  
1	
  
1	
  
1	
  
1	
  
1	
  
1	
  

Table 2

Epithelial	
  Genes	
  
Gene	
  
Cdh1	
  
Ctnnd1	
  
Epcam	
  
Krt13	
  
Krt14	
  
Krt16	
  
Krt18	
  
Krt4	
  
Krt5	
  
Krt7	
  
Krt8	
  
Zo1	
  

	
  	
  
R172H/-‐	
  (1)	
  
0.275625757	
  
0.303491284	
  
0.331532412	
  
0.467276157	
  
0.369974044	
  
0.069929071	
  
0.36366366	
  
0.091537358	
  
1	
  
0.214104185	
  
0.109274725	
  
0.442191461	
  

	
  	
  
R172H/-‐	
  (2)	
  
0.131802502	
  
0.366940979	
  
0.158274311	
  
1.206878537	
  
0.731272017	
  
0.294211673	
  
0.456454908	
  
0.373060373	
  
1.367480195	
  
0.056027745	
  
0.046238564	
  
0.521262106	
  

	
  	
  
	
  	
  
-‐/-‐	
  
+/+	
  
1.009409766	
  
0.950726541	
  
1.687692594	
  
4.874677115	
  
0.524183085	
  
0.7342291	
  
2.343444473	
  
12.34202634	
  
1	
  
1.126921409	
  
1.515886557	
  
0.803381473	
  

1	
  
1	
  
1	
  
1	
  
1	
  
1	
  
1	
  
1	
  
1	
  
1	
  
1	
  
1	
  

Table 2: Genes associated with an esophageal epithelial gene signature. Genes that
are highly downregulated in the TP53R172H/- samples as compared to both the TP53-/- and
TP53+/+ cells are hi-lighted in pink. All values are expressed as fold change over reads in
TP53+/+ cells.
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CHAPTER 4: Thesis summary and discussion
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The focus of this thesis was to describe the multiple mechanisms, in which
esophageal squamous cell carcinoma (ESCC) pathogenesis can occur and the
consequences of such genetic perturbations. Indeed the initial emphasis of this project
was on the role of mutant TP53, as it is the most commonly mutated gene in cancer and
in ESCC (Song et al., 2014; Gao et al., 2014). Previous in vitro work utilizing novel
transformed esophageal cell systems and in vivo like 3D organotypic (OTC) cultures laid
the groundwork for this project (Okawa et al., 2007; Michaylira et al., 2010). Mutant
TP53, when over expressed, in cooperation with overexpression of other oncogenes such
as EGFR and CYCLIN D1, can lead to enhancement of tumorigenic properties, such as
increased proliferation, migration, invasion, anchorage-independent growth and even
tumor formation in nude mice (Okawa et al., 2007; Michaylira et al., 2010; Ohashi et al.,
2010b).
In vitro studies of mutant TP53-mediated invasion led to the investigation of the
role of WNT signaling in ESCC and how specifically WNT10A plays a role during
tumorigenesis. WNT10A was discovered to be upregulated in an invasive gene signature
microarray in EPC2-hTERT-EGFR-TP53R175H cells. Although we did not find a direct
relationship between mutant TP53 and WNT10A, we did observe that WNT10A could
act as an oncogene in ESCC, in its own respect. Of note, our RNA-seq dataset, derived
from mouse tumor-derived cancer cells, show that, although Wnt10a was not upregulated
significantly between TP53R172H/- and TP53-/- cells, there was at least a 2-fold increase in
Wnt10a expression levels in all three cancer cell lines as compared to wildtype
esophageal cells (data not shown). Wnt6 and Wnt10b were incidentally also upregulated
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in the cancer cell lines, based on RNA-seq data. WNT10A and WNT10B may have
redundant functions, as they are closely related paralogs, induced by a duplication event
at the last common ancestor of jawed-vertebrates. WNT6, is also frequently cotranscribed with WNT10A, as they reside at the same genetic loci with no intervening
genes (Nusse, 2001). Although we did not actively pursue the impact of these other
closely related WNTs in our studies, we did note that in EPC2-hTERT-EGFR-TP53R175H
transformed cells, WNT10B was also prominently upregulated via quantitative PCR, as
compared to control cells (data not shown).
Our emphasis on WNT10A demonstrated that its upregulation could be used as an
indicator for poor prognosis in ESCC. High levels of WNT10A staining in a tumor
microarray (TMA) indicated a significant reduction in overall survival, as well as a
halved median survival time, when compared to low levels of WNT10A staining. In fact,
WNT10A staining was rarely present in normal tissue. We showed through
immunohistochemistry (IHC) staining for WNT10A that this protein was additionally
upregulated in 4-Nitroquinoline 1-oxide (4-NQO) induced hyperplasia and dysplasia of
the esophagus. Staining for WNT10A in the 4-NQO induced compound mutant TP53
mice also showed high WNT10A expression levels in the invasive squamous carcinoma
regions (data not shown). WNT10A expression was additionally highly upregulated in a
panel of ESCC cancer cell lines, when compared to normal wildtype cells. It would be
interesting to determine if WNT10A knockout mice would have the same propensity for
tumor induction and latency as wildtype mice, when treated with 4-NQO. This
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experiment could impart an in vivo role for WNT10A in ESCC tumorigenesis, and
complement the human data and in vitro functional studies.
Finally, we show in chapter 2 the definitive role of WNT10A as functionally as an
oncogene in ESCC, by promoting proliferation, migration, invasion, and stemness
properties. These findings recapitulate previous reports of WNT10A as a driver in
tumorigenesis in renal cell carcinoma (Hsu et al., 2012). In these studies, WNT10A can
induce canonical WNT signaling, in order to induce stabilization of nuclear ΒCATENIN, in order to drive downstream targets such as CCND1. Our results indicate
that over-expression of WNT10A can increase B-CATENIN levels, but we have yet to
confirm the activation of this signaling pathway, as reporter assays are hindered by the
difficulty of transient transfection in our primary keratinocyte cell line. Future studies
would focus on the downstream effects of WNT10A, such as its ability to induce the
canonical WNT signaling pathway, which receptors are utilized by WNT10A in ESCC,
and how WNT10A is being regulated in ESCC.
Previous 3D OTC invasion assays performed in the transformed esophageal cells,
demonstrated the variability of the different mutant TP53s in their ability to induce
invasion and hinted at the potential gain of function (GOF) roles of mutant TP53 in
ESCC. Nevertheless, all previous experiments utilized overexpression of mutant TP53 in
the presence of a wildtype TP53 allele. This experimental setup did not exclude potential
dominant negative functions of mutant TP53. In order to fully study the potential GOF
roles of mutant TP53, we realized the necessity to perform all future experiments in a
TP53 null background. We therefore chose to utilize Cre-Lox recombination mouse
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model systems to knockout wildtype Tp53, while introducing the R172H missense
mutation. R172H, which is the mouse homologue of the human R175H hotspot mutation,
was chosen because it had previously been described to promote carcinoma formation
and increase metastasis (Olive et al., 2004; Lang et al., 2004). Additionally, the R175H
mutation induces the highest degree of invasion in the 3D OTC model (Okawa et al.,
2007). R175H is also one of the two most commonly mutated sites of TP53 in ESCC, and
it had the unique property of being a conformational altering mutant (Petitjean et al.,
2007). By altering the conformation of the folded TP53 protein, the R175H mutation can
expose new epitopes for potential novel protein-protein or protein-DNA interactions
(Bullock and Fersht, 2001).
Ultimately, our goal was to generate a mutant TP53-driven mouse model of
ESCC, in order to study its role in tumorgenesis. Unfortunately, the murine esophagus
has many protective barriers, which inhibit transformation. Previous genetic based mouse
models of ESCC frequently require a 9-18 month tumor latency period, indicating the
resistance of this tissue to transformation (Stairs et al., 2011; Andl et al., 2014).
Additionally, the epithelium of the mouse esophagus is keratinized, unlike that in human
esophagus, which provides additional protection from extracellular insults. We found that
with L2-Cre driven Tp53 mutation alone, mice displayed relative normal morphology in
the esophagus. Therefore, we found a necessity to challenge the TP53 mutant mice with
additional carcinogenic insults. 4-NQO was utilized, as it had previously been shown to
induce invasive squamous cell carcinoma of the tongue and esophagus (Tang et al.,
2004). Our utilization of a genetic and environmental-based model of mouse ESCC may
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in fact be more physiological to human disease, as multi-factorial components contribute
to the pathogenesis of human ESCC.
Our overall findings indicate that compound mutations in TP53 indeed accelerate
the pathogenesis of ESCC in our mouse model, as compared to wildtype mice treated
with 4-NQO alone. The dynamics of tumor latency amongst the different alleles is still an
area of ongoing investigation, as we do not see differences in tumor incidence curves in
TP53R172H/+ mice versus TP53-/+ and the differences that we do see in tumor incidences
between TP53R172H/- and TP53-/- , although significant, requires increase number of mice
to power the study. Of note, previous findings in different mouse models of cancer that
are driven by mutant TP53, showed no difference in tumor latency or survival when
comparing TP53R172H/- mice versus TP53-/- mice (Muller et al., 2009; Lu et al., 2013;
Weissmueller et al., 2014; Ahronian et al., 2015).
Nevertheless, our mouse model generated additional tools for future studies on
mutant TP53 GOF as well as pathogenesis of ESCC. As we aged the mice longer beyond
the 16-week 4-NQO-treatment period, we found that our mice were able to develop
lineage-labeled metastasis to the periaortic and cervical lymph node and lungs. Another
area of active investigation is the role of mutant TP53 on induction of metastasis.
Although we are able to generate metastasis amongst our TP53 mutant mice, our system
is currently flawed to study this phenomenon. Firstly, since we are utilizing a carcinogen,
mutations may be stochastic and the specific role of mutant TP53 in inducing invasion
and metastasis may be unclear. Secondly, the dynamics of primary esophageal tumor
growth hinder our ability to study metastasis as an isolated model, since depending on
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primary tumor growth patterns (intramural versus extramural growth), mice may be
required to be euthanized before metastasis can occur.

Therefore, an accurate

interpretation of the extent of metastasis would require extremely large number of mice,
when comparing multiple genotypes. In order to simplify the system, we plan to utilize a
retro-orbital injection model to study metastatic potential of various tumor-derived
mutant TP53 cell lines. The dissemination pattern of retro-orbital injection leads to lung
metastasis, which is one of the primary metastatic niches of ESCC. Compound mutant
TP53 cells can further be genetically manipulated, such as through knockdown of the
mutant allele to generate isogenic TP53 null control cells. Additionally, specific targets of
mutant TP53 may also be perturbed genetically, in order to examine downstream
mechanisms of mutant TP53 functions.
From the lineage-labeled tumor derived cell lines that we have generated from our mouse
model, we have obtained RNA-seq data comparing wildtype, non-tumorigenic cells, to
TP53-/- and TP53R172H/- cancer cells. Since the TP53-/- and TP53R172H/- have been exposed
to additional mutagenic changes through 4-NQO treatment, and have undergone a
selection process through the culturing system, we decided to prioritize our focus on
genes that were specifically affected in the TP53R172H/-, but remain unaffected in the
TP53-/- cells. This experiment is a first pass examination of the transcriptome changes
that TP53R172H mutation may induce in ESCC. From a cursory examination of the data,
we have determined that a set of EMT-associated genes is highly dysregulated in the
TP53R172H/- cells. This finding supports our hypothesis that mutant TP53 may play a GOF
role in mediating invasion and metastasis in ESCC. In order to fully determine direct
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mechanisms of mutant TP53 GOF functions, we plan to perform a mutant TP53
chromatin immuneprecipitation sequencing (ChIP-seq) for novel mutant TP53 targets.
Previous labs have performed either ChIP-seq or RNA-seq in different mutant TP53
expressing cell lines in order to discover components of the mutant TP53 transcriptome
(Do et al., 2012; Freed-Pastor et al., 2012; Garritano et al., 2013; Xiong et al., 2014).
These datasets have utilized different mutations of TP53 and in different cancer cell
contexts. From these studies, it was shown that mutant TP53 may have a propensity to
localize at ETS-binding sites. Yet these studies also demonstrate the unique role of
mutant TP53 GOF properties, which may be both cell-type specific as well as mutant
specific. Analysis of our RNA-seq data set may indicate specific transcription factor
signatures that are being co-opted by mutant TP53 in ESCC, through protein-protein
interactions. By interrupting these interactions either through knockdown of the partner
transcription factor or re-activation of wildtype TP53 through a small molecule
compound, we may curtail the GOF effects of mutant TP53.
Our in vivo model of murine ESCC is reproducible, fast, and highly specific to
esophageal lesions. The lineage label in our ESCC model also allows for ex vivo cell
sorting as well as tracing of primary and metastatic lesions. Potentially, this mouse model
can be utilized in the future, not only to study different components of mutant TP53
induced ESCC, but also be used as mouse model for therapeutic studies.

	
   95	
  
	
  

Bibliography
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

	
   96	
  
	
  

Aberle, H., A. Bauer, J. Stappert, A. Kispert, and R. Kemler. 1997. beta-catenin is a
target for the ubiquitin-proteasome pathway. EMBO J. 16:3797–3804.
doi:10.1093/emboj/16.13.3797.
Adaimy, L., E. Chouery, H. Megarbane, S. Mroueh, V. Delague, E. Nicolas, H. Belguith,
P. de Mazancourt, and A. Megarbane. 2007. Mutation in WNT10A is associated
with an autosomal recessive ectodermal dysplasia: the odonto-onycho-dermal
dysplasia. 81.
Adorno, M., M. Cordenonsi, M. Montagner, S. Dupont, C. Wong, B. Hann, A. Solari, S.
Bobisse, M.B. Rondina, V. Guzzardo, A.R. Parenti, A. Rosato, S. Bicciato, A.
Balmain, and S. Piccolo. 2009. A Mutant-p53/Smad complex opposes p63 to
empower TGFbeta-induced metastasis. Cell. 137:87–98.
doi:10.1016/j.cell.2009.01.039.
Di Agostino, S., S. Strano, V. Emiliozzi, V. Zerbini, M. Mottolese, A. Sacchi, G.
Blandino, and G. Piaggio. 2006. Gain of function of mutant p53: the mutant
p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell
cycle regulation. Cancer Cell. 10:191–202. doi:10.1016/j.ccr.2006.08.013.
Ahronian, L.G., D.R. Driscoll, D.S. Klimstra, and B.C. Lewis. 2015. The p53R172H
mutant does not enhance hepatocellular carcinoma development and progression.
PLoS One. 10:e0123816. doi:10.1371/journal.pone.0123816.
Al-Hajj, M., M.S. Wicha, A. Benito-Hernandez, S.J. Morrison, and M.F. Clarke. 2003.
Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci.
U. S. A. 100:3983–3988. doi:10.1073/pnas.0530291100.
Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J,
HOwlader N, Tatlovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K,
Chen HS, Feuer EJ, Stinchcomb DG, E.B. (eds). 2009. No Title. Seer Cancer Stat.
Revew, 1975-2007.
Anastas, J.N., and R.T. Moon. 2013. WNT signalling pathways as therapeutic targets in
cancer. Nat. Rev. Cancer. 13:11–26. doi:10.1038/nrc3419.
Andl, C.D., B.B. Fargnoli, T. Okawa, M. Bowser, M. Takaoka, H. Nakagawa, A. KleinSzanto, X. Hua, M. Herlyn, and A.K. Rustgi. 2006. Coordinated functions of Ecadherin and transforming growth factor beta receptor II in vitro and in vivo. Cancer
Res. 66:9878–9885. doi:10.1158/0008-5472.CAN-05-4157.
Andl, T., G.F. Le Bras, N.F. Richards, G.L. Allison, H. a Loomans, M.K. Washington, F.
Revetta, R.K. Lee, C. Taylor, H.L. Moses, and C.D. Andl. 2014. Concerted loss of
TGFβ-mediated proliferation control and E-cadherin disrupts epithelial homeostasis
	
   97	
  
	
  

and causes oral squamous cell carcinoma. Carcinogenesis. 35:2602–10.
doi:10.1093/carcin/bgu194.
Ashton-Rickardt, P.G., M.G. Dunlop, Y. Nakamura, R.G. Morris, C.A. Purdie, C.M.
Steel, H.J. Evans, C.C. Bird, and A.H. Wyllie. 1989. High frequency of APC loss in
sporadic colorectal carcinoma due to breaks clustered in 5q21-22. Oncogene.
4:1169–1174.
Bänziger, C., D. Soldini, C. Schütt, P. Zipperlen, G. Hausmann, and K. Basler. 2006.
Wntless, a Conserved Membrane Protein Dedicated to the Secretion of Wnt Proteins
from Signaling Cells. Cell. 125:509–522. doi:10.1016/j.cell.2006.02.049.
Barrott, J.J., G.M. Cash, A.P. Smith, J.R. Barrow, and L.C. Murtaugh. 2011. Deletion of
mouse Porcn blocks Wnt ligand secretion and reveals an ectodermal etiology of
human focal dermal hypoplasia/Goltz syndrome. Proc. Natl. Acad. Sci. U. S. A.
108:12752–12757. doi:10.1073/pnas.1006437108.
Bass, A.J., H. Watanabe, C.H. Mermel, S. Yu, S. Perner, R.G. Verhaak, S.Y. Kim, L.
Wardwell, P. Tamayo, I. Gat-Viks, A.H. Ramos, M.S. Woo, B.A. Weir, G. Getz, R.
Beroukhim, M. O’Kelly, A. Dutt, O. Rozenblatt-Rosen, P. Dziunycz, J. Komisarof,
L.R. Chirieac, C.J. Lafargue, V. Scheble, T. Wilbertz, C. Ma, S. Rao, H. Nakagawa,
D.B. Stairs, L. Lin, T.J. Giordano, P. Wagner, J.D. Minna, A.F. Gazdar, C.Q. Zhu,
M.S. Brose, I. Cecconello, U.R. Jr, S.K. Marie, O. Dahl, R.A. Shivdasani, M.-S.
Tsao, M.A. Rubin, K.K. Wong, A. Regev, W.C. Hahn, D.G. Beer, A.K. Rustgi, and
M. Meyerson. 2009. SOX2 is an amplified lineage-survival oncogene in lung and
esophageal squamous cell carcinomas. Nat. Genet. 41:1238–1242.
doi:10.1038/ng.465.
Biechele, S., B.J. Cox, and J. Rossant. 2011. Porcupine homolog is required for canonical
Wnt signaling and gastrulation in mouse embryos. Dev. Biol. 355:275–85.
doi:10.1016/j.ydbio.2011.04.029.
Björklund, P., G. Akerström, and G. Westin. 2007. An LRP5 receptor with internal
deletion in hyperparathyroid tumors with implications for deregulated WNT/betacatenin signaling. PLoS Med. 4:e328. doi:10.1371/journal.pmed.0040328.
Bohring, A., T. Stamm, C. Spaich, C. Haase, K. Spree, U. Hehr, M. Hoffmann, S. Ledig,
S. Sel, P. Wieacker, and A. Röpke. 2009. WNT10A Mutations Are a Frequent Cause
of a Broad Spectrum of Ectodermal Dysplasias with Sex-Biased Manifestation
Pattern in Heterozygotes. Am. J. Hum. Genet. 85:97–105.
doi:10.1016/j.ajhg.2009.06.001.

	
   98	
  
	
  

Bovolenta, P., P. Esteve, J.M. Ruiz, E. Cisneros, and J. Lopez-Rios. 2008. Beyond Wnt
inhibition: new functions of secreted Frizzled-related proteins in development and
disease. J. Cell Sci. 121:737–746. doi:10.1242/jcs.026096.
Brosh, R., and V. Rotter. 2009. When mutants gain new powers: news from the mutant
p53 field. Nat. Rev. Cancer. 9:701–13. doi:10.1038/nrc2693.
Bullock, a N., and a R. Fersht. 2001. Rescuing the function of mutant p53. Nat. Rev.
Cancer. 1:68–76. doi:10.1038/35094077.
Cawthorn, W.P., A.J. Bree, Y. Yao, B. Du, N. Hemati, G. Martinez-Santibañez, and O. a
MacDougald. 2012. Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate
osteoblastogenesis through a β-catenin-dependent mechanism. Bone. 50:477–89.
doi:10.1016/j.bone.2011.08.010.
Chang, C.-J., C.-H. Chao, W. Xia, J.-Y. Yang, Y. Xiong, C.-W. Li, W.-H. Yu, S.K.
Rehman, J.L. Hsu, H.-H. Lee, M. Liu, C.-T. Chen, D. Yu, and M.-C. Hung. 2011.
p53 regulates epithelial-mesenchymal transition and stem cell properties through
modulating miRNAs. Nat. Cell Biol. 13:317–23. doi:10.1038/ncb2173.
Chicas, a, P. Molina, and J. Bargonetti. 2000. Mutant p53 forms a complex with Sp1 on
HIV-LTR DNA. Biochem. Biophys. Res. Commun. 279:383–90.
doi:10.1006/bbrc.2000.3965.
Christodoulides, C., a Scarda, M. Granzotto, G. Milan, E. Dalla Nora, J. Keogh, G. De
Pergola, H. Stirling, N. Pannacciulli, J.K. Sethi, G. Federspil, a Vidal-Puig, I.S.
Farooqi, S. O’Rahilly, and R. Vettor. 2006. WNT10B mutations in human obesity.
Diabetologia. 49:678–84. doi:10.1007/s00125-006-0144-4.
Clevers, H. 2006. Wnt/beta-catenin signaling in development and disease. Cell. 127:469–
80. doi:10.1016/j.cell.2006.10.018.
Cluzeau, C., S. Hadj-Rabia, M. Jambou, S. Mansour, P. Guigue, S. Masmoudi, E. Bal, N.
Chassaing, M.C. Vincent, G. Viot, F. Clauss, M.C. Manière, S. Toupenay, M. Le
Merrer, S. Lyonnet, V. Cormier-Daire, J. Amiel, L. Faivre, Y. De Prost, A.
Munnich, J.P. Bonnefont, C. Bodemer, and A. Smahi. 2011. Only four genes
(EDA1, EDAR, EDARADD, and WNT10A) account for 90% of
hypohidrotic/anhidrotic ectodermal dysplasia cases. Hum. Mutat. 32:70–77.
doi:10.1002/humu.21384.
Daniely, Y., G. Liao, D. Dixon, R.I. Linnoila, A. Lori, S.H. Randell, M. Oren, A.M.
Jetten, and M. Anton. 2004. Critical role of p63 in the development of a normal
esophageal and tracheobronchial epithelium. 27709:171–181.
	
   99	
  
	
  

De, A. 2011. Wnt / Ca 2 1 signaling pathway  : a brief overview The Non-canonical Wnt
Signaling Cascade. 43:745–756. doi:10.1093/abbs/gmr079.Advance.
DeLeo, A.B., G. Jay, E. Appella, G.C. Dubois, L.W. Law, and L.J. Old. 1979. Detection
of a transformation-related antigen in chemically induced sarcomas and other
transformed cells of the mouse. Proc. Natl. Acad. Sci. U. S. A. 76:2420–2424.
doi:10.1073/pnas.76.5.2420.
Dell’Orso, S., G. Fontemaggi, P. Stambolsky, F. Goeman, C. Voellenkle, M. Levrero, S.
Strano, V. Rotter, M. Oren, and G. Blandino. 2011. ChIP-on-chip analysis of in vivo
mutant p53 binding to selected gene promoters. OMICS. 15:305–312.
doi:10.1089/omi.2010.0084.
Dittmer, D., S. Pati, G. Zambetti, S. Chu, A.K. Teresky, M. Moore, C. Finlay, and A.J.
Levine. 1993. Gain of function mutations in p53. Nat. Genet. 4:42–46.
doi:10.1038/ng0593-42.
Do, P.M., L. Varanasi, S. Fan, C. Li, I. Kubacka, V. Newman, K. Chauhan, S.R. Daniels,
M. Boccetta, M.R. Garrett, R. Li, and L. a Martinez. 2012. Mutant p53 cooperates
with ETS2 to promote etoposide resistance. Genes Dev. 26:830–45.
doi:10.1101/gad.181685.111.
Domyan, E.T., E. Ferretti, K. Throckmorton, Y. Mishina, S.K. Nicolis, and X. Sun. 2011.
Signaling through BMP receptors promotes respiratory identity in the foregut via
repression of Sox2. Development. 138:971–981. doi:10.1242/dev.053694.
Eliyahu, D., A. Raz, P. Gruss, D. Givol, and M. Oren. 1984. Participation of p53 cellular
tumour antigen in transformation of normal embryonic cells. Lett. to Nat. 312:646–
649.
Enzinger, P.C., and R.J. Mayer. 2003. Esophageal cancer. N. Engl. J. Med. 349:2241–52.
doi:10.1056/NEJMra035010.
Freed-Pastor, W. a, H. Mizuno, X. Zhao, A. Langerød, S.-H. Moon, R. RodriguezBarrueco, A. Barsotti, A. Chicas, W. Li, A. Polotskaia, M.J. Bissell, T.F. Osborne,
B. Tian, S.W. Lowe, J.M. Silva, A.-L. Børresen-Dale, A.J. Levine, J. Bargonetti,
and C. Prives. 2012. Mutant p53 disrupts mammary tissue architecture via the
mevalonate pathway. Cell. 148:244–58. doi:10.1016/j.cell.2011.12.017.
Freed-Pastor, W. a, and C. Prives. 2012. Mutant p53: one name, many proteins. Genes
Dev. 26:1268–86. doi:10.1101/gad.190678.112.
Fu, L., C. Zhang, L.Y. Zhang, S.S. Dong, L.H. Lu, J. Chen, Y. Dai, Y. Li, K.L. Kong,
D.L. Kwong, and X.Y. Guan. 2011. Wnt2 secreted by tumour fibroblasts promotes
	
  100	
  
	
  

tumour progression in oesophageal cancer by activation of the Wnt/beta-catenin
signalling pathway. Gut. 60:1635–1643. doi:10.1136/gut.2011.241638.
Gao, N., P. White, and K.H. Kaestner. 2009. Establishment of Intestinal Identity and
Epithelial-Mesenchymal Signaling by Cdx2. Dev. Cell. 16:588–599.
doi:10.1016/j.devcel.2009.02.010.
Gao, Y.-B., Z.-L. Chen, J.-G. Li, X.-D. Hu, X.-J. Shi, Z.-M. Sun, F. Zhang, Z.-R. Zhao,
Z.-T. Li, Z.-Y. Liu, Y.-D. Zhao, J. Sun, C.-C. Zhou, R. Yao, S.-Y. Wang, P. Wang,
N. Sun, B.-H. Zhang, J.-S. Dong, Y. Yu, M. Luo, X.-L. Feng, S.-S. Shi, F. Zhou, F.W. Tan, B. Qiu, N. Li, K. Shao, L.-J. Zhang, L.-J. Zhang, Q. Xue, S.-G. Gao, and J.
He. 2014. Genetic landscape of esophageal squamous cell carcinoma. Nat. Genet.
46:1097–102. doi:10.1038/ng.3076.
Garritano, S., a Inga, F. Gemignani, and S. Landi. 2013. More targets, more pathways
and more clues for mutant p53. Oncogenesis. 2:e54. doi:10.1038/oncsis.2013.15.
Giraldez, A.J., and S.M. Cohen. 2003. Wingless and Notch signaling provide cell
survival cues and control cell proliferation during wing development. Development.
130:6533–43. doi:10.1242/dev.00904.
Gómez-Orte, E., B. Sáenz-Narciso, S. Moreno, and J. Cabello. 2013. Multiple functions
of the noncanonical Wnt pathway. Trends Genet. 29:545–53.
doi:10.1016/j.tig.2013.06.003.
Goss, A.M., Y. Tian, T. Tsukiyama, E.D. Cohen, D. Zhou, M.M. Lu, T.P. Yamaguchi,
and E.E. Morrisey. 2009. Wnt2/2b and beta-catenin signaling are necessary and
sufficient to specify lung progenitors in the foregut. Dev. Cell. 17:290–8.
doi:10.1016/j.devcel.2009.06.005.
Groden, J., A. Thliveris, W. Samowitz, M. Carlson, L. Gelbert, H. Albertsen, G. Joslyn,
J. Stevens, L. Spirio, M. Robertson, L. Sargeant, K. Krapcho, E. Wolff, R. Burt, J.P.
Hughes, J. Warrington, J. McPherson, J. Wasmuth, D. Le Paslier, H. Abderrahim, D.
Cohen, M. Leppert, and R. White. 1991. Identification and characterization of the
familial adenomatous polyposis coli gene. Cell. 66:589–600. doi:10.1016/00928674(81)90021-0.
Gross, J.C., V. Chaudhary, K. Bartscherer, and M. Boutros. 2012. Active Wnt proteins
are secreted on exosomes. Nat. Cell Biol. 14:1036–1045. doi:10.1038/ncb2574.
Grumolato, L., G. Liu, P. Mong, R. Mudbhary, R. Biswas, R. Arroyave, S. Vijayakumar,
A.N. Economides, and S.A. Aaronson. 2010. Canonical and noncanonical Wnts use
a common mechanism to activate completely unrelated coreceptors. 2517–2530.
doi:10.1101/gad.1957710.).
	
  101	
  
	
  

Grzeschik, K.-H., D. Bornholdt, F. Oeffner, A. König, M. del Carmen Boente, H. Enders,
B. Fritz, M. Hertl, U. Grasshoff, K. Höfling, V. Oji, M. Paradisi, C. Schuchardt, Z.
Szalai, G. Tadini, H. Traupe, and R. Happle. 2007. Deficiency of PORCN, a
regulator of Wnt signaling, is associated with focal dermal hypoplasia. Nat. Genet.
39:833–835. doi:10.1038/ng2052.
Harada, H., H. Nakagawa, K. Oyama, M. Takaoka, C.D. Andl, B. Jacobmeier, A. von
Werder, G.H. Enders, O.G. Opitz, and A.K. Rustgi. 2003. Telomerase induces
immortalization of human esophageal keratinocytes without p16INK4a inactivation.
Mol. Cancer Res. 1:729–738.
Harris-Johnson, K.S., E.T. Domyan, C.M. Vezina, and X. Sun. 2009. beta-Catenin
promotes respiratory progenitor identity in mouse foregut. Proc. Natl. Acad. Sci. U.
S. A. 106:16287–16292. doi:10.1073/pnas.0902274106.
He, T., A.B. Sparks, C. Rago, H. Hermeking, L. Zawel, L.T. Costa, P.J. Morin, B.
Vogelstein, and K.W. Kinzler. 1998. Identification of c- MYC as a Target of the
APC Pathway. 281:1509–1513.
Holland, J.D., A. Klaus, A.N. Garratt, and W. Birchmeier. 2013. Wnt signaling in stem
and cancer stem cells. Curr. Opin. Cell Biol. 25:254–264.
doi:10.1016/j.ceb.2013.01.004.
Hsu, R.-J., J.-Y. Ho, T.-L. Cha, D.-S. Yu, C.-L. Wu, W.-P. Huang, P. Chu, Y.-H. Chen,
J.-T. Chen, and C.-P. Yu. 2012. WNT10A plays an oncogenic role in renal cell
carcinoma by activating WNT/β-catenin pathway. PLoS One. 7:e47649.
doi:10.1371/journal.pone.0047649.
Hu, N., J. Huang, M.R. Emmert-buck, Z. Tang, M.J. Roth, C. Wang, S.M. Dawsey, G.
Li, W. Li, Q. Wang, X. Han, T. Ding, C. Giffen, A.M. Goldstein, P.R. Taylor, C.
Sciences, and G. Gln. 2001. Frequent Inactivation of the TP53 Gene in Esophageal
Squamous Cell Carcinoma from a High-Risk Population in China. 7:883–891.
Ikeya, M., S.M.K. Lee, J.E. Johnson, P. Mcmahon, and S. Takada. 1997. Wnt signalling
required for expansion of neural crest and CNS progenitors. 389:966–970.
Itin, P.H. 2014. Etiology and pathogenesis of ectodermal dysplasias. Am. J. Med. Genet.
Part A. 164:2472–2477. doi:10.1002/ajmg.a.36550.
Janda, C.Y., D. Waghray, A.M. Levin, C. Thomas, and K.C. Garcia. 2012. Structural
Basis of Wnt Recognition by Frizzled. Science (80-. ). 337:59–64.
Ji, H., R.J.A. Goode, F. Vaillant, S. Mathivanan, E.A. Kapp, R.A. Mathias, G.J.
Lindeman, J.E. Visvader, and R.J. Simpson. 2011. Proteomic profiling of secretome
	
  102	
  
	
  

and adherent plasma membranes from distinct mammary epithelial cell
subpopulations. Proteomics. 11:4029–4039. doi:10.1002/pmic.201100102.
Kalabis, J., G.S. Wong, M.E. Vega, M. Natsuizaka, E.S. Robertson, M. Herlyn, H.
Nakagawa, and A.K. Rustgi. 2012. Isolation and characterization of mouse and
human esophageal epithelial cells in 3D organotypic culture. Nat. Protoc. 7:235–
246.
Kinugasa, H., K.A. Whelan, K. Tanaka, M. Natsuizaka, A. Long, A. Guo, S. Kagawa, S.
Srinivasan, G. Manti, K. Yamamoto, D.K. St. Clair, N.G. Avadhani, J.A. Diehl, and
Hi. Nakagawa. 2015. Mitochondrial SOD2 regulates epithelial-mesenchymal
transition and cell populations defined by differential CD44 expression. Oncogene.
Kinzler, K.W., M.C. Nilbert, L.K. Su, B. Vogelstein, T.M. Bryan, D.B. Levy, K.J. Smith,
A.C. Preisinger, P. Hedge, and D. McKechnie. 1991. Identification of FAP locus
genes from chromosome 5q21. Science. 253:661–665. doi:10.1126/science.1651562.
Kirikoshi, H., S. Inoue, H. Sekihara, and M. Katoh. 2001a. Expression of WNT10A in
human cancer. Int. J. Oncol. 19:997–1001.
Kirikoshi, H., H. Sekihara, and M. Katoh. 2001b. WNT10A and WNT6, clustered in
human chromosome 2q35 region with head-to-tail manner, are strongly coexpressed
in SW480 cells. Biochem. Biophys. Res. Commun. 283:798–805.
doi:10.1006/bbrc.2001.4855.
Kirikoshi, H., H. Sekihara, and M. Katoh. 2001c. Up-regulation of WNT10A by tumor
necrosis factor alpha and Helicobacter pylori in gastric cancer. Int. J. Oncol.
19:533–536.
Kishida, S., H. Yamamoto, S. Ikeda, M. Kishida, I. Sakamoto, S. Koyama, and A.
Kikuchi. 1998. Axin, a negative regulator of the Wnt signaling pathway, directly
interacts with adenomatous polyposis coli and regulates the stabilization of  ??catenin. J. Biol. Chem. 273:10823–10826. doi:10.1074/jbc.273.18.10823.
Koesters, R., R. Ridder, A. Kopp-Schneider, D. Betts, V. Adams, F. Niggli, J. Briner, and
M.V.K. Doeberitz. 1999. Mutational activation of the β-catenin proto-oncogene is a
common event in the development of Wilms’ tumors. Cancer Res. 59:3880–3882.
Kogan-Sakin, I., Y. Tabach, Y. Buganim, a Molchadsky, H. Solomon, S. Madar, I.
Kamer, P. Stambolsky, a Shelly, N. Goldfinger, S. Valsesia-Wittmann, a Puisieux, a
Zundelevich, E.N. Gal-Yam, C. Avivi, I. Barshack, M. Brait, D. Sidransky, E.
Domany, and V. Rotter. 2011. Mutant p53(R175H) upregulates Twist1 expression
and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell
Death Differ. 18:271–81. doi:10.1038/cdd.2010.94.
	
  103	
  
	
  

Komekado, H., H. Yamamoto, T. Chiba, and A. Kikuchi. 2007. Glycosylation and
palmitoylation of Wnt-3a are coupled to produce an active form of Wnt-3a. Genes
Cells. 12:521–34. doi:10.1111/j.1365-2443.2007.01068.x.
Kongkham, P.N., P.A. Northcott, S.E. Croul, C.A. Smith, M.D. Taylor, and J.T. Rutka.
2010. The SFRP family of WNT inhibitors function as novel tumor suppressor
genes epigenetically silenced in medulloblastoma. Oncogene. 29:3017–3024.
doi:10.1038/onc.2010.32.
Korinek, V., N. Barker, P. Moerer, E. van Donselaar, G. Huls, P.J. Peters, and H.
Clevers. 1998. Depletion of epithelial stem-cell compartments in the small intestine
of mice lacking Tcf-4. Nat. Genet. 19:379–383. doi:10.1038/1270.
Korkut, C., B. Ataman, P. Ramachandran, J. Ashley, R. Barria, N. Gherbesi, and V.
Budnik. 2009. Trans-Synaptic Transmission of Vesicular Wnt Signals through
Evi/Wntless. Cell. 139:393–404. doi:10.1016/j.cell.2009.07.051.
Krämer, A., J. Green, J. Pollard, and S. Tugendreich. 2014. Causal analysis approaches in
Ingenuity Pathway Analysis. Bioinformatics. 30:523–30.
doi:10.1093/bioinformatics/btt703.
Kremenevskaja, N., R. von Wasielewski, a S. Rao, C. Schöfl, T. Andersson, and G.
Brabant. 2005. Wnt-5a has tumor suppressor activity in thyroid carcinoma.
Oncogene. 24:2144–54. doi:10.1038/sj.onc.1208370.
Kurasawa, Y., K. Kozaki, A. Pimkhaokham, T. Muramatsu, H. Ono, T. Ishihara, N.
Uzawa, I. Imoto, T. Amagasa, and J. Inazawa. 2012. Stabilization of phenotypic
plasticity through mesenchymal-specific DNA hypermethylation in cancer cells.
Oncogene. 31:1963–1974. doi:10.1038/onc.2011.373.
Kurayoshi, M., N. Oue, H. Yamamoto, M. Kishida, A. Inoue, T. Asahara, W. Yasui, and
A. Kikuchi. 2006. Expression of Wnt-5a is correlated with aggressiveness of gastric
cancer by stimulating cell migration and invasion. Cancer Res. 66:10439–48.
doi:10.1158/0008-5472.CAN-06-2359.
Kusserow, A., K. Pang, C. Sturm, M. Hrouda, J. Lentfer, H.A. Schmidt, U. Technau, A.
von Haeseler, B. Hobmayer, M.Q. Martindale, and T.W. Holstein. 2005.
Unexpected complexity of the Wnt gene family in a sea anemone. Nature. 433:156–
160. doi:10.1038/nature03158.
Lamouille, S., J. Xu, and R. Derynck. 2014. Molecular mechanisms of epithelialmesenchymal transition. Nat. Rev. Mol. Cell Biol. 15:178–96. doi:10.1038/nrm3758.

	
  104	
  
	
  

Lane, D.P. 1992. Cancer. p53, guardian of the genome. Nature. 358:15–16.
doi:10.1038/358015a0.
Lane, D.P., and L. V Crawford. 1980. The complex between simian virus 40 T antigen
and a specific host protein. Proc. R. Soc. Lond. B. Biol. Sci. 210:451–463.
doi:10.1098/rspb.1980.0146.
Lang, G. a, T. Iwakuma, Y.-A. Suh, G. Liu, V.A. Rao, J.M. Parant, Y. a Valentin-Vega,
T. Terzian, L.C. Caldwell, L.C. Strong, A.K. El-Naggar, and G. Lozano. 2004. Gain
of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.
Cell. 119:861–72. doi:10.1016/j.cell.2004.11.006.
Li, J., G.W. Peet, D. Balzarano, X. Li, P. Massa, R.W. Barton, and K.B. Marcu. 2001.
Novel NEMO/IkappaB kinase and NF-kappa B target genes at the pre-B to
immature B cell transition. J. Biol. Chem. 276:18579–90.
doi:10.1074/jbc.M100846200.
Lin, D.-C., X.-L. Du, and M.-R. Wang. 2009. Protein alterations in ESCC and clinical
implications: a review. Dis. Esophagus. 22:9–20. doi:10.1111/j.14422050.2008.00845.x.
Linzer, D.I., and A.J. Levine. 1979. Characterization of a 54K dalton cellular SV40
tumor antigen present in SV40-transformed cells and uninfected embryonal
carcinoma cells. Cell. 17:43–52. doi:10.1016/0092-8674(79)90293-9.
Liu, K., M. Jiang, Y. Lu, H. Chen, J. Sun, S. Wu, W.Y. Ku, H. Nakagawa, Y. Kita, S.
Natsugoe, J.H. Peters, A. Rustgi, M.W. Onaitis, A. Kiernan, X. Chen, and J. Que.
2013. Sox2 cooperates with inflammation-mediated stat3 activation in the malignant
transformation of foregut basal progenitor cells. Cell Stem Cell. 12:304–315.
doi:10.1016/j.stem.2013.01.007.
Liu, K., S. Ling, and W.-C. Lin. 2011. TopBP1 mediates mutant p53 gain of function
through NF-Y and p63/p73. Mol. Cell. Biol. 31:4464–81. doi:10.1128/MCB.0557411.
Long, A., V. Giroux, K. a Whelan, K.E. Hamilton, M.-P. Tétreault, K. Tanaka, J.-S. Lee,
A.J. Klein-Szanto, H. Nakagawa, and A.K. Rustgi. 2015. WNT10A promotes an
invasive and self-renewing phenotype in esophageal squamous cell carcinoma.
Carcinogenesis. 36:598–606. doi:10.1093/carcin/bgv025.
Lu, D., Y. Zhao, R. Tawatao, H.B. Cottam, M. Sen, L.M. Leoni, T.J. Kipps, M. Corr, and
D.A. Carson. 2004. Activation of the Wnt signaling pathway in chronic lymphocytic
leukemia.
	
  105	
  
	
  

Lu, F., A.B. Gladden, and J.A. Diehl. 2003. An Alternatively Spliced Cyclin D1 Isoform,
Cyclin D1b, Is a Nuclear Oncogene. Cancer Res. 63:7056–7061.
Lu, X., D.P. Liu, and Y. Xu. 2013. The gain of function of p53 cancer mutant in
promoting mammary tumorigenesis. Oncogene. 32:2900–6.
doi:10.1038/onc.2012.299.
Macdonald, B.T., K. Tamai, and X. He. 2009. Review Wnt / b -Catenin Signaling  :
Components , Mechanisms , and Diseases. Dev. Cell. 17:9–26.
doi:10.1016/j.devcel.2009.06.016.
Major, M.B., N.D. Camp, J.D. Berndt, X. Yi, S.J. Goldenberg, C. Hubbert, T.L. Biechele,
A.-C. Gingras, N. Zheng, M.J. Maccoss, S. Angers, and R.T. Moon. 2007. Wilms
tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science.
316:1043–1046. doi:10.1126/science/1141515.
Malanchi, I., A. Santamaria-Martínez, E. Susanto, H. Peng, H.-A. Lehr, J.-F. Delaloye,
and J. Huelsken. 2012. Interactions between cancer stem cells and their niche govern
metastatic colonization. Nature. 481:85–9. doi:10.1038/nature10694.
Malkin, D., F.P. Li, L.C. Strong, J.F. Fraumeni, C.E. Nelson, D.H. Kim, J. Kassel, M.A.
Gryka, F.Z. Bischoff, and M.A. Tainsky. 1990. Germ line p53 mutations in a
familial syndrome of breast cancer, sarcomas, and other neoplasms. Science.
250:1233–1238. doi:10.1126/science.1978757.
Mandard, a M., P. Hainaut, and M. Hollstein. 2000. Genetic steps in the development of
squamous cell carcinoma of the esophagus. Mutat. Res. 462:335–42.
Mani, S.A., W. Guo, M.J. Liao, E.N. Eaton, A. Ayyanan, A.Y. Zhou, M. Brooks, F.
Reinhard, C.C. Zhang, M. Shipitsin, L.L. Campbell, K. Polyak, C. Brisken, J. Yang,
and R.A. Weinberg. 2008. The Epithelial-Mesenchymal Transition Generates Cells
with Properties of Stem Cells. Cell. 133:704–715. doi:10.1016/j.cell.2008.03.027.
Mao, J., J. Wang, B. Liu, W. Pan, G.H. Farr, C. Flynn, H. Yuan, S. Takada, D.
Kimelman, L. Li, and D. Wu. 2001. Low-density lipoprotein receptor-related
protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol.
Cell. 7:801–809. doi:10.1016/S1097-2765(01)00224-6.
Mao, W., W. Zheng, and Z. Ling. 2011. MINI-REVIEW Epidemiologic Risk Factors for
Esophageal Cancer Development. 12:2461–2466.
Marino, S., M. Vooijs, H. Van Der Gulden, J. Jonkers, and A. Berns. 2000. Induction of
medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the
	
  106	
  
	
  

external granular layer cells of the cerebellum. Genes Dev. 14:994–1004.
doi:10.1101/gad.14.8.994.
Mcmahon, A., and A. Bradleyt. 1990. The Wnt-1 ( in & l ) Proto-Oncogene Is Required
for Development of a Large Region of the Mouse Brain. 62:1073–1085.
Mcmahon, A.P., and R.T. Moon. 1999. Ectopic Expression of the Proto-Oncogene int-1
in Xenopus Embryos Leads to Duplication of the Embryonic Axis. 58:1075–1084.
Meek, D.W., and C.W. Anderson. 2009. Posttranslational modification of p53:
cooperative integrators of function. Cold Spring Harb. Perspect. Biol. 1.
doi:10.1101/cshperspect.a000950.
Michaylira, C.Z., G.S. Wong, C.G. Miller, C.M. Gutierrez, H. Nakagawa, R. Hammond,
A.J. Klein-Szanto, J.-S. Lee, S.B. Kim, M. Herlyn, J.A. Diehl, P. Gimotty, and A.K.
Rustgi. 2010. Periostin, a cell adhesion molecule, facilitates invasion in the tumor
microenvironment and annotates a novel tumor-invasive signature in esophageal
cancer. Cancer Res. 70:5281–92. doi:10.1158/0008-5472.CAN-10-0704.
Minami, Y., I. Oishi, M. Endo, and M. Nishita. 2010. Ror-family receptor tyrosine
kinases in noncanonical Wnt signaling: Their implications in developmental
morphogenesis and human diseases. Dev. Dyn. 239:1–15. doi:10.1002/dvdy.21991.
Minoo, P., G. Su, H. Drum, P. Bringas, and S. Kimura. 1999. Defects in
tracheoesophageal and lung morphogenesis in Nkx2.1(-/-) mouse embryos. Dev.
Biol. 209:60–71. doi:10.1006/dbio.1999.9234.
Montserrat, N., A. Gallardo, D. Escuin, L. Catasus, J. Prat, F.J. Gutiérrez-Avignó, G.
Peiró, A. Barnadas, and E. Lerma. 2011. Repression of E-cadherin by SNAIL,
ZEB1, and TWIST in invasive ductal carcinomas of the breast: A cooperative
effort? Hum. Pathol. 42:103–110. doi:10.1016/j.humpath.2010.05.019.
Muller, P. a J., P.T. Caswell, B. Doyle, M.P. Iwanicki, E.H. Tan, S. Karim, N.
Lukashchuk, D. a Gillespie, R.L. Ludwig, P. Gosselin, A. Cromer, J.S. Brugge, O.J.
Sansom, J.C. Norman, and K.H. Vousden. 2009. Mutant p53 drives invasion by
promoting integrin recycling. Cell. 139:1327–41. doi:10.1016/j.cell.2009.11.026.
Muller, P. a J., and K.H. Vousden. 2013. P53 Mutations in Cancer. Nat. Cell Biol. 15:2–
8. doi:10.1038/ncb2641.
Mulligan, K.A., C. Fuerer, W. Ching, M. Fish, K. Willert, and R. Nusse. 2011. Secreted
Wingless-interacting molecule ( Swim ) promotes long-range signaling by
maintaining Wingless solubility. doi:10.1073/pnas.1119197109//DCSupplemental.www.pnas.org/cgi/doi/10.1073/pnas.1119197109.
	
  107	
  
	
  

Najdi, R., K. Proffitt, S. Sprowl, S. Kaur, J. Yu, T.M. Covey, D.M. Virshup, and M.L.
Waterman. 2012. A uniform human Wnt expression library reveals a shared
secretory pathway and unique signaling activities. Differentiation. 84:203–213.
doi:10.1016/j.diff.2012.06.004.
Nakagawa, H., T.C. Wang, L. Zukerberg, R. Odze, K. Togawa, G.H. May, J. Wilson, and
a K. Rustgi. 1997. The targeting of the cyclin D1 oncogene by an Epstein-Barr virus
promoter in transgenic mice causes dysplasia in the tongue, esophagus and
forestomach. Oncogene. 14:1185–90. doi:10.1038/sj.onc.1200937.
Nakagawa, H., L. Zukerberg, K. Togawa, S.J. Meltzer, T. Nishihara, and A.K. Rustgi.
1995. Human cyclin D1 oncogene and esophageal squamous cell carcinoma.
Cancer. 76:541–549. doi:10.1002/1097-0142(19950815)76:4<541::AIDCNCR2820760402>3.0.CO;2-I.
Napier, K.J., M. Scheerer, and S. Misra. 2014. Esophageal cancer: A Review of
epidemiology, pathogenesis, staging workup and treatment modalities. World J.
Gastrointest. Oncol. 6:112–20. doi:10.4251/wjgo.v6.i5.112.
Narita, T., S. Sasaoka, K. Udagawa, T. Ohyama, N. Wada, S.-I. Nishimatsu, S. Takada,
and T. Nohno. 2005. Wnt10a is involved in AER formation during chick limb
development. Dev. Dyn. 233:282–7. doi:10.1002/dvdy.20321.
Nawaz, S., J. Klar, M. Wajid, M. Aslam, M. Tariq, J. Schuster, S.M. Baig, and N. Dahl.
2009. WNT10A missense mutation associated with a complete odonto-onychodermal dysplasia syndrome. Eur. J. Hum. Genet. 17:1600–1605.
doi:10.1038/ejhg.2009.81.
Nishihira, T., Y. Hashimoto, M. Katayama, S. Mori, and T. Kuroki. 1993. Molecular and
cellular features of esophageal cancer cells. J. Cancer Res. Clin. Oncol. 119:441–
449.
Nishisho, I., Y. Nakamura, Y. Miyoshi, Y. Miki, H. Ando, A. Horii, K. Koyama, J.
Utsunomiya, S. Baba, and P. Hedge. 1991. Mutations of chromosome 5q21 genes in
FAP and colorectal cancer patients. Science. 253:665–669.
doi:10.1126/science.1651563.
Niwa, Y., S. Yamada, M. Koike, M. Kanda, T. Fujii, G. Nakayama, H. Sugimoto, S.
Nomoto, M. Fujiwara, and Y. Kodera. 2014. Epithelial to mesenchymal transition
correlates with tumor budding and predicts prognosis in esophageal squamous cell
carcinoma. J. Surg. Oncol. 110:764–9. doi:10.1002/jso.23694.
Nusse, R. 2001. An ancient cluster of Wnt paralogues. 17:9525.
	
  108	
  
	
  

Nusse, R., A. Brown, J. Papkoff, P. Scambler, G. Shackleford, A. McMahon, H. Varmus,
and R. Moon. 1991. A new nomenclature for int-1 and Related Genes: The Wnt
Gene Family. Cell. 64:231–232.
Nusse, R., and H.E. Varmus. 1982. Many tumors induced by the mouse mammary tumor
virus contain a provirus integrated in the same region of the host genome. Cell.
31:99–109. doi:10.1016/0092-8674(82)90409-3.
Nüsslein-Volhard, C., and E. Wieschaus. 1980. Mutations affecting segment number and
polarity in Drosophila. Nature. 287:795–801. doi:10.1038/287795a0.
Ohashi, S., M. Natsuizaka, S. Naganuma, S. Kagawa, S. Kimura, H. Itoh, R.A. Kalman,
M. Nakagawa, D.S. Darling, D. Basu, P.A. Gimotty, A.J. Klein-Szanto, J.A. Diehl,
M. Herlyn, and H. Nakagawa. 2011. A NOTCH3-mediated squamous cell
differentiation program limits expansion of EMT-competent cells that express the
ZEB transcription factors. Cancer Res. 71:6836–6847. doi:10.1158/00085472.CAN-11-0846.
Ohashi, S., M. Natsuizaka, G.S. Wong, C.Z. Michaylira, K.D. Grugan, D.B. Stairs, J.
Kalabis, M.E. Vega, R. a Kalman, M. Nakagawa, A.J. Klein-Szanto, M. Herlyn, J.A.
Diehl, A.K. Rustgi, and H. Nakagawa. 2010a. Epidermal growth factor receptor and
mutant p53 expand an esophageal cellular subpopulation capable of epithelial-tomesenchymal transition through ZEB transcription factors. Cancer Res. 70:4174–84.
doi:10.1158/0008-5472.CAN-09-4614.
Ohashi, S., M. Natsuizaka, G.S. Wong, C.Z. Michaylira, K.D. Grugan, D.B. Stairs, J.
Kalabis, M.E. Vega, R.A. Kalman, M. Nakagawa, A.J. Klein-Szanto, M. Herlyn,
J.A. Diehl, A.K. Rustgi, and H. Nakagawa. 2010b. Epidermal growth factor receptor
and mutant p53 expand an esophageal cellular subpopulation capable of epithelialto-mesenchymal transition through ZEB transcription factors. Cancer Res. 70:4174–
4184. doi:10.1158/0008-5472.CAN-09-4614.
Okawa, T., C.Z. Michaylira, J. Kalabis, D.B. Stairs, H. Nakagawa, C.D. Andl, C.N.
Johnstone, A.J. Klein-Szanto, W.S. El-Deiry, E. Cukierman, M. Herlyn, and A.K.
Rustgi. 2007. The functional interplay between EGFR overexpression, hTERT
activation, and p53 mutation in esophageal epithelial cells with activation of stromal
fibroblasts induces tumor development, invasion, and differentiation. Genes Dev.
21:2788–803. doi:10.1101/gad.1544507.
Okubo, T., L.H. Pevny, and B.L.M. Hogan. 2006. Sox2 is required for development of
taste bud sensory cells. Genes Dev. 20:2654–2659. doi:10.1101/gad.1457106.

	
  109	
  
	
  

Olive, K.P., D. a Tuveson, Z.C. Ruhe, B. Yin, N. a Willis, R.T. Bronson, D. Crowley,
and T. Jacks. 2004. Mutant p53 gain of function in two mouse models of LiFraumeni syndrome. Cell. 119:847–60. doi:10.1016/j.cell.2004.11.004.
Olivier, M., M. Hollstein, and P. Hainaut. 2010. TP53 mutations in human cancers:
origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2.
doi:10.1101/cshperspect.a001008.
Opitz, O.G., H. Harada, Y. Suliman, B. Rhoades, N.E. Sharpless, R. Kent, L. Kopelovich,
and H. Nakagawa. 2002. A mouse model of human oral-esophageal cancer. J. Clin.
Invest. 110:761–769. doi:10.1172/JCI200215324.Introduction.
Ordway, J.M., J.A. Bedell, R.W. Citek, A. Nunberg, A. Garrido, R. Kendall, J.R.
Stevens, D. Cao, R.W. Doerge, Y. Korshunova, H. Holemon, J.D. McPherson, N.
Lakey, J. Leon, R.A. Martienssen, and J.A. Jeddeloh. 2006. Comprehensive DNA
methylation profiling in a human cancer genome identifies novel epigenetic targets.
Carcinogenesis. 27:2409–2423. doi:10.1093/carcin/bgl161.
Oren, M., and V. Rotter. 2010. Mutant p53 gain-of-function in cancer. Cold Spring Harb.
Perspect. Biol. 2:a001107. doi:10.1101/cshperspect.a001107.
Oren, M., and V. Rotter. 2015. Mutant p53 Gain-of-Function in Cancer. 1–16.
Parsa, R., a Yang, F. McKeon, and H. Green. 1999. Association of p63 with proliferative
potential in normal and neoplastic human keratinocytes. J. Invest. Dermatol.
113:1099–105. doi:10.1046/j.1523-1747.1999.00780.x.
Petitjean, A., E. Mathe, S. Kato, C. Ishioka, S. V, P. Hainaut, and M. Olivier. 2007.
Impact of Mutant p53 Functional Properties on TP53 Mutation Patterns and Tumor
Phenotype  : Lessons from Recent Developments in the IARC TP53 Database. Hum.
Mutat. 28:622–629. doi:10.1002/humu.
Polakis, P. 2000. Wnt signaling and cancer Wnt signaling and cancer. 1837–1851.
doi:10.1101/gad.14.15.1837.
Polakis, P. 2007. The many ways of Wnt in cancer. Curr. Opin. Genet. Dev. 17:45–51.
doi:10.1016/j.gde.2006.12.007.
Que, J., T. Okubo, J.R. Goldenring, K.-T. Nam, R. Kurotani, E.E. Morrisey, O. Taranova,
L.H. Pevny, and B.L.M. Hogan. 2007. Multiple dose-dependent roles for Sox2 in the
patterning and differentiation of anterior foregut endoderm. Development.
134:2521–2531. doi:10.1242/dev.003855.

	
  110	
  
	
  

Reddy, S., T. Andl, A. Bagasra, M. Min, D.J. Epstein, E.E. Morrisey, and S.E. Millar.
2001. Characterization of Wnt gene expression in developing and postnatal hair
follicles and identi ® cation of Wnt5a as a target of Sonic hedgehog in hair follicle
morphogenesis. 107.
Reya, T., A.W. Duncan, L. Ailles, J. Domen, D.C. Scherer, K. Willert, L. Hintz, R.
Nusse, and I.L. Weissman. 2003. A role for Wnt signalling in self-renewal of
haematopoietic stem cells. Nature. 423:409–414. doi:10.1038/nature01593.
Rice, T.W., E.H. Blackstone, and V.W. Rusch. 2010. A cancer staging primer: esophagus
and esophagogastric junction. J. Thorac. Cardiovasc. Surg. 139:527–9.
doi:10.1016/j.jtcvs.2009.11.002.
Rivera, M., W.J. Kim, J. Wells, D.R. Driscoll, B.W. Brannigan, M. Han, J.C. Kim, A.P.
Feinberg, W.L. Gerlad, S.O. Vargas, L. Chin, A.J. Iafrate, D.W. Bell, and D.A.
Haber. 2007. An X Chromosome Gene, WTX, Is commonly Inactivated in Wilms
Tumor. 642–646.
Rodriguez, P., S. Da Silva, L. Oxburgh, F. Wang, B.L.M. Hogan, and J. Que. 2010. BMP
signaling in the development of the mouse esophagus and forestomach.
Development. 137:4171–6. doi:10.1242/dev.056077.
Ross, S.E., N. Hemati, K.A. Longo, C.N. Bennett, P.C. Lucas, R.L. Erickson, and O.A.
MacDougald. 2000. Inhibition of adipogenesis by Wnt signaling. Science. 289:950–
953. doi:10.1126/science.289.5481.950.
Rotter, V. 1983. P53, a Transformation-Related Cellular-Encoded Protein, Can Be
ochemical Marker for the DetectiUsed As a Bion of Primary Mouse Tumor Cells.
Proc. Natl. Acad. Sci. U. S. A. 80:2613–7.
Salahshor, S., and J.R. Woodgett. 2005. The links between axin and carcinogenesis. J.
Clin. Pathol. 58:225–236. doi:10.1136/jcp.2003.009506.
Sammons, M.A., J. Zhu, A.M. Drake, and S.L. Berger. 2015. TP53 engagement with the
genome occurs in distinct local chromatin environments via pioneer factor activity.
179–188. doi:10.1101/gr.181883.114.25.
Sato, N., L. Meijer, L. Skaltsounis, P. Greengard, and A.H. Brivanlou. 2004.
Maintenance of pluripotency in human and mouse embryonic stem cells through
activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat.
Med. 10:55–63. doi:10.1038/nm979.
Satoh, S., Y. Daigo, Y. Furukawa, T. Kato, N. Miwa, T. Nishiwaki, T. Kawasoe, H.
Ishiguro, M. Fujita, T. Tokino, Y. Sasaki, S. Imaoka, M. Murata, T. Shimano, Y.
	
  111	
  
	
  

Yamaoka, and Y. Nakamura. 2000. AXIN1 mutations in hepatocellular carcinomas,
and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat.
Genet. 24:245–250. doi:10.1038/73448.
Schambony, A., and D. Wedlich. 2007. Wnt-5A/Ror2 regulate expression of XPAPC
through an alternative noncanonical signaling pathway. Dev. Cell. 12:779–92.
doi:10.1016/j.devcel.2007.02.016.
Schneider, C.A., W.S. Rasband, and K.W. Eliceiri. 2012. NIH Image to ImageJ: 25 years
of image analysis. Nat. Methods. 9:671–675. doi:10.1038/nmeth.2089.
Semënov, M. V., X. Zhang, and X. He. 2008. DKK1 antagonizes Wnt signaling without
promotion of LRP6 internalization and degradation. J. Biol. Chem. 283:21427–
21432. doi:10.1074/jbc.M800014200.
Sharma, R.P., and V.L. Chopra. 1976. Effect of the Wingless (wg1) mutation on wing
and haltere development in Drosophila melanogaster. Dev. Biol. 48:461–465.
doi:10.1016/0012-1606(76)90108-1.
Shi, Z.-Z., Y.-Y. Jiang, J.-J. Hao, Y. Zhang, T.-T. Zhang, L. Shang, S.-G. Liu, F. Shi, and
M.-R. Wang. 2014. Identification of putative target genes for amplification within
11q13.2 and 3q27.1 in esophageal squamous cell carcinoma. Clin. Transl. Oncol.
16:606–15. doi:10.1007/s12094-013-1124-z.
Shtutman, M., J. Zhurinsky, I. Simcha, C. Albanese, M. D’Amico, R. Pestell, and A.
Ben-Ze’ev. 1999. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway.
Proc. Natl. Acad. Sci. U. S. A. 96:5522–5527. doi:10.1073/pnas.96.10.5522.
Shu, W., Y.Q. Jiang, M.M. Lu, and E.E. Morrisey. 2002. Wnt7b regulates mesenchymal
proliferation and vascular development in the lung. Development. 129:4831–4842.
Sidow, A. 1992. Diversification of the Wnt gene family on the ancestral lineage of
vertebrates. 89:5098–5102.
Song, H., M. Hollstein, and Y. Xu. 2007. p53 gain-of-function cancer mutants induce
genetic instability by inactivating ATM. Nat. Cell Biol. 9:573–580.
doi:10.1038/ncb1571.
Song, Y., L. Li, Y. Ou, Z. Gao, E. Li, X. Li, W. Zhang, J. Wang, L. Xu, Y. Zhou, X. Ma,
L. Liu, Z. Zhao, X. Huang, J. Fan, L. Dong, G. Chen, L. Ma, J. Yang, L. Chen, M.
He, M. Li, X. Zhuang, K. Huang, K. Qiu, G. Yin, G. Guo, Q. Feng, P. Chen, Z. Wu,
J. Wu, L. Ma, J. Zhao, L. Luo, M. Fu, B. Xu, B. Chen, Y. Li, T. Tong, M. Wang, Z.
Liu, D. Lin, X. Zhang, H. Yang, J. Wang, and Q. Zhan. 2014. Identification of
	
  112	
  
	
  

genomic alterations in oesophageal squamous cell cancer. Nature. 509:91–5.
doi:10.1038/nature13176.
Srinivas, S., T. Watanabe, C. Lin, M. Chris, Y. Tanabe, T.M. Jessell, and F. Costantini.
2001. Cre reporter strains produced by targeted insertion of EYFP and ECFP into
the ROSA26 locus.
Staal, F.J.T., T.C. Luis, and M.M. Tiemessen. 2008. WNT signalling in the immune
system: WNT is spreading its wings. Nat. Rev. Immunol. 8:581–93.
doi:10.1038/nri2360.
Stairs, D.B., L.J. Bayne, B. Rhoades, M.E. Vega, T.J. Waldron, J. Kalabis, A. KleinSzanto, J.-S. Lee, J.P. Katz, J.A. Diehl, A.B. Reynolds, R.H. Vonderheide, and A.K.
Rustgi. 2011. Deletion of p120-catenin results in a tumor microenvironment with
inflammation and cancer that establishes it as a tumor suppressor gene. Cancer Cell.
19:470–83. doi:10.1016/j.ccr.2011.02.007.
Stambolsky, P., Y. Tabach, G. Fontemaggi, L. Weisz, R. Maor-Aloni, Z. Siegfried, Z.
Sigfried, I. Shiff, I. Kogan, M. Shay, E. Kalo, G. Blandino, I. Simon, M. Oren, and
V. Rotter. 2010. Modulation of the vitamin D3 response by cancer-associated
mutant p53. Cancer Cell. 17:273–85. doi:10.1016/j.ccr.2009.11.025.
Stevens, J.R., G. a Miranda-Carboni, M. a Singer, S.M. Brugger, K.M. Lyons, and T.F.
Lane. 2010. Wnt10b deficiency results in age-dependent loss of bone mass and
progressive reduction of mesenchymal progenitor cells. J. Bone Miner. Res.
25:2138–47. doi:10.1002/jbmr.118.
Summerhurst, K., M. Stark, J. Sharpe, D. Davidson, and P. Murphy. 2008. 3D
representation of Wnt and Frizzled gene expression patterns in the mouse embryo at
embryonic day 11.5 (Ts19). Gene Expr. Patterns. 8:331–48.
doi:10.1016/j.gep.2008.01.007.
Suzuki, H., D.N. Watkins, K.-W. Jair, K.E. Schuebel, S.D. Markowitz, W.D. Chen, T.P.
Pretlow, B. Yang, Y. Akiyama, M. Van Engeland, M. Toyota, T. Tokino, Y.
Hinoda, K. Imai, J.G. Herman, and S.B. Baylin. 2004. Epigenetic inactivation of
SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet.
36:417–422. doi:10.1038/ng1330.
Takada, R., Y. Satomi, T. Kurata, N. Ueno, S. Norioka, H. Kondoh, T. Takao, and S.
Takada. 2006. Monounsaturated fatty acid modification of Wnt protein: its role in
Wnt secretion. Dev. Cell. 11:791–801. doi:10.1016/j.devcel.2006.10.003.

	
  113	
  
	
  

Tamai, K., X. Zeng, C. Liu, X. Zhang, Y. Harada, Z. Chang, and X. He. 2004. A
Mechanism for Wnt Coreceptor Activation. Mol. Cell. 13:149–156.
doi:10.1016/S1097-2765(03)00484-2.
Tang, X.H., B. Knudsen, D. Bemis, S. Tickoo, and L.J. Gudas. 2004. Oral Cavity and
Esophageal Carcinogenesis Modeled in Carcinogen-Treated Mice. Clin. Cancer Res.
10:301–313.
Taylor, P.R., C.C. Abnet, and S.M. Dawsey. 2013. Squamous dysplasia--the precursor
lesion for esophageal squamous cell carcinoma. Cancer Epidemiol. Biomarkers
Prev. 22:540–52. doi:10.1158/1055-9965.EPI-12-1347.
Thiery, J.P., H. Acloque, R.Y.J. Huang, and M.A. Nieto. 2009. Epithelial-Mesenchymal
Transitions in Development and Disease. Cell. 139:871–890.
doi:10.1016/j.cell.2009.11.007.
Thomas, K.R., and M.R. Capecchi. 1990. Targeted disruption of the murine int-1 protooncogene resulting in severe abnormalities in midbrain and cerebellar development.
Nature. 346:847–850. doi:10.1038/346847a0.
Toh, Y., E. Oki, K. Ohgaki, Y. Sakamoto, S. Ito, A. Egashira, H. Saeki, Y. Kakeji, M.
Morita, Y. Sakaguchi, T. Okamura, and Y. Maehara. 2010. Alcohol drinking,
cigarette smoking, and the development of squamous cell carcinoma of the
esophagus: molecular mechanisms of carcinogenesis. Int. J. Clin. Oncol. 15:135–44.
doi:10.1007/s10147-010-0057-6.
Tziotzios, C., G. Petrof, L. Liu, a Verma, E.K. Wedgeworth, J.E. Mellerio, and J. a
McGrath. 2014. Clinical features and WNT10A mutations in seven unrelated cases
of Schöpf-Schulz-Passarge syndrome. Br. J. Dermatol. 171:1211–4.
doi:10.1111/bjd.13158.
Vannier, C., K. Mock, T. Brabletz, and W. Driever. 2013. Zeb1 regulates E-cadherin and
Epcam (epithelial cell adhesion molecule) expression to control cell behavior in
early zebrafish development. J. Biol. Chem. 288:18643–59.
doi:10.1074/jbc.M113.467787.
Vincent, A., N. Omura, S.-M. Hong, A. Jaffe, J. Eshleman, and M. Goggins. 2011.
Genome-wide analysis of promoter methylation associated with gene expression
profile in pancreatic adenocarcinoma. Clin. Cancer Res. 17:4341–4354.
doi:10.1158/1078-0432.CCR-10-3431.
Visel, A., C. Thaller, and G. Eichele. 2004. GenePaint.org: an atlas of gene expression
patterns in the mouse embryo. Nucleic Acids Res. 32:D552–D556.
doi:10.1093/nar/gkh029.
	
  114	
  
	
  

Vousden, K.H., and C. Prives. 2009. Blinded by the Light: The Growing Complexity of
p53. Cell. 137:413–31. doi:10.1016/j.cell.2009.04.037.
Wang, J., and G.M. Shackleford. 1996. Murine Wnt10a and Wnt10b: cloning and
expression in developing limbs, face and skin of embryos and in adults. Oncogene.
13:1537–1544.
Wang, L.D., J.Y. Hong, S.L. Qiu, H. Gao, and C.S. Yang. 1993. Accumulation of p53
protein in human esophageal precancerous lesions: A possible early biomarker for
carcinogenesis. Cancer Res. 53:1783–1787.
Wang, S.-P., W.-L. Wang, Y.-L. Chang, C.-T. Wu, Y.-C. Chao, S.-H. Kao, A. Yuan, C.W. Lin, S.-C. Yang, W.-K. Chan, K.-C. Li, T.-M. Hong, and P.-C. Yang. 2009. p53
controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug.
Nat. Cell Biol. 11:694–704. doi:10.1038/ncb1875.
Wang, X., H. Ouyang, Y. Yamamoto, P.A. Kumar, T.S. Wei, R. Dagher, M. Vincent, X.
Lu, A.M. Bellizzi, K.Y. Ho, C.P. Crum, W. Xian, and F. McKeon. 2011. Residual
embryonic cells as precursors of a Barrett’s-like metaplasia. Cell. 145:1023–35.
doi:10.1016/j.cell.2011.05.026.
Wang, X., V. Reid Sutton, J. Omar Peraza-Llanes, Z. Yu, R. Rosetta, Y.-C. Kou, T.N.
Eble, A. Patel, C. Thaller, P. Fang, and I.B. Van den Veyver. 2007. Mutations in Xlinked PORCN, a putative regulator of Wnt signaling, cause focal dermal
hypoplasia. Nat. Genet. 39:836–838. doi:10.1038/ng2057.
Wei, W., M.-S. Chua, S. Grepper, and S.K. So. 2011. Soluble Frizzled-7 receptor inhibits
Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin.
Mol. Cancer. 10:16. doi:10.1186/1476-4598-10-16.
Weissmueller, S., E. Manchado, M. Saborowski, J.P. Morris, E. Wagenblast, C. a Davis,
S.-H. Moon, N.T. Pfister, D.F. Tschaharganeh, T. Kitzing, D. Aust, E.K. Markert, J.
Wu, S.M. Grimmond, C. Pilarsky, C. Prives, A. V Biankin, and S.W. Lowe. 2014.
Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF
receptor β signaling. Cell. 157:382–94. doi:10.1016/j.cell.2014.01.066.
Wells, J.M., and D.A. Melton. 1999. Ertebrate ndoderm evelopment. 393–410.
Wielenga, V.J., R. Smits, V. Korinek, L. Smit, M. Kielman, R. Fodde, H. Clevers, and
S.T. Pals. 1999. Expression of CD44 in Apc and Tcf mutant mice implies regulation
by the WNT pathway. Am. J. Pathol. 154:515–523. doi:10.1016/S00029440(10)65297-2.

	
  115	
  
	
  

Willert, K., J.D. Brown, E. Danenberg, and A.W. Duncan. 2003. Wnt proteins are lipidmodified and can act as stem cell growth factors. 423.
Willert, K., and R. Nusse. 2012. Wnt proteins. Cold Spring Harb. Perspect. Biol.
4:a007864. doi:10.1101/cshperspect.a007864.
Wong, G.S., P. Habibollahi, P. Heidari, J.-S. Lee, A.J. Klein-Szanto, T.J. Waldron, P.
Gimotty, H. Nakagawa, P.R. Taylor, T.C. Wang, U. Mahmood, and A.K. Rustgi.
2013a. Optical imaging of periostin enables early endoscopic detection and
characterization of esophageal cancer in mice. Gastroenterology. 144:294–7.
doi:10.1053/j.gastro.2012.10.030.
Wong, G.S., J.-S. Lee, Y.-Y. Park, a J. Klein-Szanto, T.J. Waldron, E. Cukierman, M.
Herlyn, P. Gimotty, H. Nakagawa, and a K. Rustgi. 2013b. Periostin cooperates with
mutant p53 to mediate invasion through the induction of STAT1 signaling in the
esophageal tumor microenvironment. Oncogenesis. 2:e59.
doi:10.1038/oncsis.2013.17.
Wong, G.S., and a K. Rustgi. 2013. Matricellular proteins: priming the tumour
microenvironment for cancer development and metastasis. Br. J. Cancer. 108:755–
61. doi:10.1038/bjc.2012.592.
Wong, S.C.C., S.F.E. Lo, K.C. Lee, J.W.P. Yam, J.K.C. Chan, and W.L. Wendy Hsiao.
2002. Expression of frizzled-related protein and Wnt-signalling molecules in
invasive human breast tumours. J. Pathol. 196:145–153. doi:10.1002/path.1035.
Xiong, S., H. Tu, M. Kollareddy, V. Pant, Q. Li, Y. Zhang, J.G. Jackson, Y.-A. Suh, A.C.
Elizondo-Fraire, P. Yang, G. Chau, M. Tashakori, A.R. Wasylishen, Z. Ju, H.
Solomon, V. Rotter, B. Liu, A.K. El-Naggar, L. a Donehower, L.A. Martinez, and
G. Lozano. 2014. Pla2g16 phospholipase mediates gain-of-function activities of
mutant p53. Proc. Natl. Acad. Sci. U. S. A. 111:11145–50.
doi:10.1073/pnas.1404139111.
Xu, J., J. Reumers, J.R. Couceiro, F. De Smet, R. Gallardo, S. Rudyak, A. Cornelis, J.
Rozenski, A. Zwolinska, J.-C. Marine, D. Lambrechts, Y.-A. Suh, F. Rousseau, and
J. Schymkowitz. 2011. Gain of function of mutant p53 by coaggregation with
multiple tumor suppressors. Nat. Chem. Biol. 7:285–295.
doi:10.1038/nchembio.546.
Yang, a, R. Schweitzer, D. Sun, M. Kaghad, N. Walker, R.T. Bronson, C. Tabin, a
Sharpe, D. Caput, C. Crum, and F. McKeon. 1999. P63 Is Essential for Regenerative
Proliferation in Limb, Craniofacial and Epithelial Development. Nature. 398:714–8.
doi:10.1038/19539.
	
  116	
  
	
  

Yang, L., X. Wu, Y. Wang, K. Zhang, J. Wu, Y.-C. Yuan, X. Deng, L. Chen, C.C.H.
Kim, S. Lau, G. Somlo, and Y. Yen. 2011. FZD7 has a critical role in cell
proliferation in triple negative breast cancer. Oncogene. 30:4437–46.
doi:10.1038/onc.2011.145.
Yokoyama, A., H. Kato, T. Yokoyama, T. Tsujinaka, M. Muto, T. Omori, T. Haneda, Y.
Kumagai, H. Igaki, M. Yokoyama, and H. Watanabe. 2002. Genetic polymorphisms
of alcohol and aldehyde dehydrogenases and glutathione S -transferase M1 and
drinking , smoking , and diet in Japanese men with esophageal squamous cell
carcinoma. 23:1851–1859.
Yu, W.Y., J.M.W. Slack, and D. Tosh. 2005. Conversion of columnar to stratified
squamous epithelium in the developing mouse oesophagus. Dev. Biol. 284:157–170.
doi:10.1016/j.ydbio.2005.04.042.
Zhao, J.S., W.J. Li, D. Ge, P.J. Zhang, J.J. Li, C.L. Lu, X.D. Ji, D.X. Guan, H. Gao, L.Y.
Xu, E.M. Li, H. Soukiasian, H.P. Koeffler, X.F. Wang, and D. Xie. 2011. Tumor
initiating cells in Esophageal squamous cell carcinomas express high levels of
CD44. PLoS One. 6. doi:10.1371/journal.pone.0021419.

	
  117	
  
	
  

